Incidence and survival of childhood cancers in Singapore, 1968-1997: A population-based study by SONG YUSHAN
INCIDENCE AND SURVIVAL OF CHILDHOOD CANCERS 






















A THESIS SUBMITTED FOR THE DEGREE OF  
MASTER OF SCIENCE (CLINICAL SCIENCE) 
DEPARTEMENT OF COMMUNITY, OCCUPATIONAL 
AND FAMILY MEDICINE 




I am most grateful to my supervisors, Associate Professor Chia Kee Seng, for his providing 
of data from Singapore Cancer Registry, for his most helpful guidance on methodology of 
data mining and epidemiological analysis.  I also sincerely appreciate my supervisor’s 
useful criticisms and encouragements regarding to the research project. 
 
I am most indebted to the National University of Singapore for offering me the opportunity 
to pursue postgraduate studies, and awarding me the scholarship. 
 
I wish to give my great thanks to Mr. Cheung Kwok Hang, staff of Centre for Molecular 
Epidemiology (CME), who provided support in data connecting and coding; Mrs. Gao Wei, 
staff of CME, who gave consultant on manipulating statistical software. I am also thankful 
to Mr. Tan Chuen Seng (Staff of CME), Betty and Yee Hwee (staffs of Singapore Cancer 
Registry) for their help and support. 
 
Finally, I would like to express my thankfulness to Ms. Tan Kim Luan, Ms. Chia Meowhah, 
Mr. Nirantars Saurabh and all the other people who have helped me and encouraged me 










ACKNOWLEDGMENTS..…………………………………………………………I   
CONTENTS.....…………………………………………………….………………II 
SUMMARY…..………………………………………………….…………………III 
LISTING OF TABLES….……………………………………..………………..VIII 
LISTING OF FIGURES .…………………………………....…………………...IX 
LISTING OF ABBREVIATIONS USED IN THIS PAPER.……………………X 
CHAPTER 1  INTRODUCTION..………………………….……………………..1 
CHAPTER 2  LITERATURE REVIEW…………………….…………………….3 
 
     INCIDENCE OF CHILDHOOD CANCERS…… …..….………………………………4 
     TRENDS OF INCIDENCE FOR CHILDHOOD CANCERS…………………………..6 
LEUKEMIA………………..………………………………....…………………......6 
LYMPHOMAS..……………………..………………………...………..…………..7 
CENTRAL NERVOUS SYSTEM TUMORS…..………………………..…………8 
OTHER CHILDHOOD CANCERS………………...………………………………9 
      RISK FACTORS RELATED TO INCIDENCE OF CHILDHOOD CANCERS...…...10 
      GENETIC RISK FACTORS.………………..…………………………………….10 






     SURVIVAL OF CHILDHOOD CANCERS………………..…………...……………..17 
 LEUKEMIA………………………..……………………...……………………….19 
LYMPHOMAS..……………………..…………..……………………..………….20 
CENTRAL NERVOUS SYSTEM TUMORS………………………..……………20 
 II 
HEPATIC TUMORS………………..………………..………………..…………..21 
OTHER CHILDHOOD CANCERS………………..………..…………………….21 
     PROGNOSTIC FACTORS OF SURVIVAL………………..……………..…….…….22 
     SUMMARY…….…………………..……….…………………..……….……………..25 
     OBJECTIVE……………………………………………………………………………25 
CHAPTER 3   MATERIALS AND METHODS………………………………..26 
      STUDY SUBJECTS….………………………………………………………………..26 
      STATISTICAL ANALYSES……………………………………………………….....27 
 INCIDENCE ANALYSIS…………………………………………………………27 
 SURVIVAL ANALYSIS………………………………………………………….28 
CHARPTER 4   RESULTS……………………………………………………...30 
      AGE AND ETHNIC PATTERN..………………………………………………….….30 
      INCIDENCE……………………………………………………………………….…..31 
 LEUKEMIA…………………………………………………………………….….34 
 LYMPHOMA……………………………………………………………………...35 
 BRAIN AND SPINAL NEOPLASMS………………………………………….…36 
 SYMPATHETIC NERVOUS SYSTEM TUMORS……………………………....37 
 RETINOBLASTOMA……………………………………………………………..38 
 RENAL TUMORS………………………………………………………………...38 
 HEPATIC TUMORS……………………………………………………………....39 
 MALIGNANT BONE TUMORS………………………………………………….39 
 SOFT TISSUE SARCOMAS……………………………………………………...40 
 GERM CELL AND GONADAL NEOPLASMS………………………………….41 
 CARCINOMAS AND EPITHELIAL NEOPLASMS.……………………………42 
 ETHNIC DIFFERENCE OF INCIDENCE………………………………………..42 
      SURVIVAL……………………………………………………………………………43 
 LYMPHOID LEUKEMIA..……………………………………………………….44 
 ACUTE NON-LYMPHOCYTIC LEUKEMIA…………………………………...45 
 NON-HODGKIN’S LYMPHOMA………………………………………………..45 




 GERM CELL TUMORS…………………………………………………………..47 
 RENAL TUMORS…………………………………………………………….......47 
 SOFT TISSUE SARCOMAS……………………………………………………...48 
CHARPTER 5  DISCUSSION.…………………………………………………49 
      INCIDENCE….……………………………………………………………………….49 
      SURVIVAL..………………………………………………………………………….59 































                                                             Summary 
 
Childhood cancer is the leading cause of disease-related death among children in developed 
countries. With the growing incidence and its severe impact on the patients’ families, 
increasing attention is given on the study of childhood cancers.  
 
The etiology of childhood cancers is complicated and no obvious factors have been 
confirmed yet. With the implementation of population-based cancer registry in most 
developed countries, description and inter-countries comparison of incidence and survival 
rates for childhood cancers became possible. Increasing trend of incidence for childhood 
cancers were reported worldwide which was believed to be due to improvements in 
diagnostic techniques and cancer ascertainment. The survival rates for most childhood 
cancers have improved substantially over the last several decades. The advancement of 
modern treatment and increased accessibility to health care have undoubtedly contributed 
to the improvement. Since 1967, a nationwide cancer registry has been established in 
Singapore. Yet no systematic studies on trends of incidence and survival rates for 
childhood cancers have been conducted. In this study, we reviewed data of childhood 
cancers from the Singapore Cancer Registry to describe the incidence, trends of incidence 
rates, and trends of survival rates for childhood cancers from 1968 to 1997. 
 
Data of 2129 children patients were included in this study. There were 1168 boys (54.9%) 
and 961 girls (45.1%). The incidence peak age was at 5 years or younger. The incidence of 
overall childhood cancers increased from 98.3 per million in 1968-77, to 102.6 per million 
in 1978-87 and 127.0 per million in 1988-97. The three most commonly diagnosed 
 V 
childhood cancers over the 30 years were childhood leukemia (38.2%), CNS tumors 
(14.2%) and childhood lymphomas (9.8%). Hepatic tumors were least common (1.6%). 
The age-standardized rate (ASR) of leukemia was highest among all groups of childhood 
cancers of 42.7 per million children per year. The ASR was 10.2 per million children per 
year for lymphomas and 15.0 per million children per year for CNS tumors. Our study 
confirmed an increasing trend for most childhood cancers over thirty years, such as 
leukemia, CNS tumors, sympathetic nervous system tumors, retinoblastoma, hepatic 
tumors, and ‘germ cell and gonadal neoplasms’. The increases were most obvious among 
tumors sensitive to improved diagnostic technologies like imaging and bone marrow 
morphology. There was little or no increase for tumors which were not sensitive to 
diagnostic technology like lymphomas, bone and soft tissue sarcoma. 
 
Altogether 2066 cases were suitable for survival analysis. The overall 5-year survival rate 
was 45.4% (95%CI: 43.2-47.6%) for overall childhood cancers over the thirty years in 
Singapore. The 5-year survival rates increased from 32.8% (95%CI: 29.3-36.6) in 1968-
1977, to 45.3% (95%CI: 41.5-49.3) in 1978-1987; and to 57.0% (95%CI: 53.2-60.7) in 
1988-1997.  The 5-year survival rate for lymphoid leukemia also increased from 24.8% 
(95%CI: 18.7-32.0%) in 1968-77 to 40.4% (95%CI: 33.2-48.2%) in 1978-87 to 58.2% 
(95%CI: 50.8-65.2%) in 1988-97. The survival rate of leukemia in Singapore was about 
10% lower than those in Japan, and 20% lower than those in SEER. The reason may be due 
to insufficient supportive care for children with cancer in Singapore and the adoption of 
inferior treatment protocol like UKALL X. Because of the lack of local publications related 
to the treatment of other childhood cancers, it is difficult to analyze the reason or make 
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comparison with other countries. Great improvements were achieved by local doctors and 
pediatric oncologists, while more reports or studies on treatment protocols of childhood 
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Chapter 1 Introduction 
Childhood cancer is the second most common cause of death in children, after 
accidental death in developed countries (Bernard et al., 1993; Li et al., 1999). The 
profile of the incidence of childhood cancer is useful for epidemiologists and health 
policy-makers as it is an increasingly important public health problem. Although the 
number of children younger than 15 years old in Singapore decreased steadily from 
804,800 in the 1970’s, to 653,100 in the 1980’s and to 628,100 in the 1990’s(Saw, 
1981), reversal of family planning policies, this age group increased to 700,800 in 
2000. This group currently represents 21.5% of total population (Department of 
Statistics, 2001).  
From 1968 to 1987, the three most common forms of childhood cancers in Singapore 
were leukemia, lymphomas and malignancies of the brain and nervous system 
(Shanmugaratnam et al., 1983; Lee et al., 1988; 1992). In Singapore during 1983-
1987, these three tumor types together account for 66.7% tumors in male children and 
63.3% in female children.  During that period, the relative frequency of leukemia was 
39.2% of total cancers for male children and 37.3% for female children. Brain and 
nervous system tumors accounted for 15.1% of childhood cancers in boys and 18.3% 
in girls. Lymphomas accounted for 12.4% in male children and 7.7% in female 
children. These cancer patterns are very similar to those for children in most countries 
(Lee et al., 1992).   
Unlike adult cancers which are classified by anatomic site, classification of childhood 
cancers was based on histological type. This standard set by International 
Classification of Childhood Cancers (ICCC), were widely followed worldwide since 
1990’s (Kramarova & Stiller, 1996). The ICCC divides childhood cancers into 12 
major groups and each group with up to 6 subgroups. Most groups or subgroups of 
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childhood cancers were rare and with low incidence rates. A comprehensive 
population-based cancer registry provides a useful resource to calculate reliable 
incidence. High quality data and standardized classification of childhood cancers 
made it possible for description and comparison of incidence between countries and 
over time.  
The interpretation of trends of incidence rate is complicated as the causes are 
multifactorial. Analysis on trend of incidence rates reflect not only the true changes of 
incidence, but also the confounding factors like improvement of diagnostic methods, 
the accuracy of census estimates, and changes in morphology classifications 
(Terracini et al, 2001; Gurney, 1999). The changes in classification may cause 
artificial modification of incidence rates among groups or subgroups. The increased 
incidence of brain cancer over the past two to three decades are believed to be due to 
improved detection and reporting coincident with the advent of magnetic resonance 
imaging (MRI) in the mid-1980s (Gurney, 1999). It is not clear whether there is a 
similar trend in Singapore. Therefore it is very important to closely examine the local 
records of childhood cancer so that accurate conclusions can be reached.  
With improvements in therapy, the long-term survival rates for the major childhood 
cancers have improved in USA (Linet et al., 1999). A similar trend is also found in 
most developed countries (Terracini et al. 2001). Long-term survival rates of children 
with ALL were 40%-50% in the 1970s, increasing to 70%-80% in the 1990s in 
European countries (Pastore et al., 2001a). Survival rates of children with central 
nervous system (CNS) tumors had also improved gradually in the last 30 years even 
though they were more difficult to treat than other cancers.  
Population-based cancer registries provide reliable pool of data. Due to the relative 
rarity of childhood cancer, large populations and long time periods are required for 
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reliable observation and calculation of incidence and survival rates (Breslow & 
Langholz, 1983). In addition, cancer registries also provide a unique public health 
perspective for the purpose of resource allocation (Pastore et al., 2001a). Cancer 
registries have been in existence for 30 years in Singapore and have amassed 
important and large amount of data on cancer incidence in Singapore. Although trends 
in adult cancers have been published regularly by the Singapore Cancer Registry, 
similar analyses have not been carried out locally.  In this study we utilized childhood 
cancer registries in Singapore to describe the incidence and survival rates of 
















Chapter 2 Literature Review 
Childhood cancers show different features and patterns compared to adult cancers. 
Therefore it is a great challenge for scientists to understand the mechanisms and 
patterns. Accurately maintained population-based cancer registries provide an 
efficient and useful source of data for analysis. The study of incidence rates of 
childhood cancers and their trend over long period help to ascertain the estimates of 
survival and also provide a useful approach to evaluate the treatment and management 
of these cancers. This review will focus on two aspects of childhood cancers using 
population-based cancer registry studies. The first section reviews the trends of 
incidence of childhood cancers in some countries, and the possible risk factors for 
childhood cancers; the second section briefly covers some trends of population-based 
survival rates of childhood cancers in recent decades and the prognostic factors. 
 
Incidence of childhood cancers 
In developed countries, childhood cancer is an important public health problem. It is 
not only the second most common cause of death (Higginson et al., 1992; Green et al., 
1997), but also exacts a heavy mental and economic burden to families. Leukemia is 
the most common cancer affecting children, accounting for one third of malignancies 
in children (Parkin et al., 1988a). Acute lymphocytic leukemia (ALL) accounts for the 
majority of leukemia cases. Central nervous system (CNS) tumor is the second most 
common cancer in children, accounting for 17-25% of total childhood cancers (Parkin 
et al., 1988a). Lymphoma, accounting for 15% of all childhood cancer, is the third 
most frequent cancer affecting children. Altogether leukemia, CNS tumors and 
lymphoma accounted for 57% of cancers found in children younger than 20 years old 
in Surveillance Epidemiology and End Results (SEER) study (SEER, 2005). 
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Table 1 (Parkin et al., 1998) listed the data from several registries around the world. 
The global incidence rates of cancers appeared to be higher in developed countries 
such as Europe, Australia and the United States. Nordic countries such as Sweden and 
Finland, which established cancer registration earlier than other countries/regions, 
showed higher ASRs of 154.3 and 153.5 per million respectively in the 1980s, and 
believed to be more comprehensive and reliable. Systematically and completely 
registered data contributed to the high ASRs and were believed reflecting the true 
rates. The Singapore Cancer Registry was established in 1967, and the ASR of 
childhood cancers was 109.3 per million in 1968-1997. 
Table 1. Incidence of cancer among children in selected countries 
ASR (per million) 
 
Country, city/program 
(race, ethnicity); period 
The year cancer 
registration being 
established Male Female All 
Developed countries/regions     
Singapore (Chinese);1968-1997 1967 116.2 101.5 109.3 
Japan; 1980-1992 1975 127.0 105.1 116.3 
Canada; 1982-1991 1969 162.1 135.6 149.2 
USA, SEER,White; 1983-1992 1972 160.7 139.3 150.3 
USA, SEER, Black; 1983-1992 1972 116.3 119.6 117.9 
Colombia, Cali; 1982-1991 1962 133.1 114.3 123.7 
Sweden; 1983-1989 1958 157.4 151.2 154.3 
Finland; 1980-1989 1952 163.5 143.1 153.5 
Australia; 1982-1991 1977 156.1 128.1 142.4 
Hong Kong; 1980-1989 1963 151.1 111.6 132.1 
Developing countries/regions     
China, Tianjin; 1981-1992 1978 116.2 93.0 104.9 
Egypt, Alexandria; 1980-1989 1960 121.8 81.1 101.4 
India, Bombay; 1980-1992 1963 91.3 62.4 77.3 
 
The low incidence of leukemia in India and Africa led to criticisms of underestimates 
due to diagnostic imprecision. (Little, 1999) Likewise, imprecise diagnostics and 
classification can also lead to overestimation and fallaciously high incidence as a 
result. For example in a study from Hong Kong, during 1982-91, many cases were 
double reported and miscoded. This resulted in much higher incidence than those after 
1989 since when double-entry of data were eliminated (Li, 1999).  
 6 
Direct standardized methods were performed to calculate the incidence rates in table 1.  
The classification of childhood tumors in the age group (0-14 years old) relates for the 
most part to the tumor’s histological type rather than the site-based type used for adult 
cancer classification. The most frequently used coding scheme for histology is the 
morphology section of the International Classification of Diseases for Oncology 
(ICD-O). Histology includes the examination of tissue sections from biopsy of the 
primary tumor or of the metastasis, or of cytological or hematological specimens 
(Parkin et al., 1988b).   
 
Trends of incidence for childhood cancers 
Time trends of incidence helped researchers to understand the mechanism of 
childhood cancers and the impact of the improvement in diagnostic technologies. 
 
Leukemia 
Incidence of leukemia around the world was believed to have experienced an increase 
when the new technology was introduced in the late 1970s which helped in 
diagnosing cancer effectively. Earlier report by SEER found a short-term increase of 
leukemia age-standardized rate (ASR) in 1983-86. A ‘jump model’ (a lower stable 
incidence rate before mid-1980s, and a higher constant rate there after) suggested that 
the abrupt increase occurring from the 9 registries in the USA might be due to 
improvement in diagnosis. The relative flat trend was also observed in other studies 
since 1980s (Linet et al., 1999). In a population-based study on childhood cancers in 
northeast Hungary, during 1984–1998, there showed a significant increase in average 
annual percent change (AAPC), accounting to 0.7% in the incidence of leukemia, and 
of 1.9% in ALL (Jakab et al., 2002). In a study of SEER by McNeil et al. (2002), the 
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incidence of ALL increased from 19 in 1973-77 to 29 per million children per year in 
1993-98. Significant linear increases in ALL with an average annual increase of 0.7% 
were also found in England during 1954-1998 (McNally et al, 2001a). The data of 
5,379 ALL children patients younger than 20 years old were calculated by SEER from 
1973 to 1998, and the ALL incidence rates were found to increase over the study 
period (McNeil et al., 2002).. 
The analysis by Hjalgrim et al (2003) found that incidence rates of childhood 
leukemia in the Nordic countries had been stable during the last 20 years (1982-2003); 
these findings may be due to relatively fixed etiology and diagnostic techniques since 
the prior years.  
A decreasing trend was only sporadically reported in several countries during certain 
period of time, which may due to random variation or artificial effects. There were 
downward trends in incidence of overall leukemia during 1981–96 in Costa Rica . It 
might be due to unclear etiology, which caused the high incidence rates to be recorded 
in 1981-90 (Monge et al, 2002). Similarly in Hong Kong, data was more accurately 
registered after 1989 and exclusive ID numbers was incorporated, which brought 
about a decrease in reported incidence (Li et al, 1999). 
 
Lymphomas 
The trends of incidence for childhood lymphomas were inconsistent over time and 
varied among countries. No consensus has been reached for the changes of lymphoma 
by studies. A slight increase of lymphomas was reported which was due to the 
increase incidence of HD, while NHL exhibited stable rates in UK from the 
Manchester Children Tumor Registry (MTCR), 1954-1998 (McNally et al., 2001a; 
Weidmann et al., 1999). Unlike other studies, this study covered a 45-yesr time span; 
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the diagnostic artifact may play a role in the observed temporal changes.  A somewhat 
higher incidence, than was previously reported, of childhood NHL in Sweden during 
1975-94 was thought to be due to a more thorough data collection and reexamination 
of source materials (Samuelsson et al., 1999).  
Average annual percentage change in incidence rates and corresponding confidence 
intervals were estimated in the study by Gurney et al. (1996). Among children in the 
U.S. younger than 15 years there was a 0.2% average yearly decrease (95% CI: -1.5, 
1.2) in the incidence rates of non-Hodgkin’s lymphoma (NHL), and 0.3% average 
yearly decrease (95% CI: -1.8, 1.3) in the incidence rates of Hodgkin’s disease (HD) 
during 1974-91. In another study by SEER, a moderate but significant decrease 
(P=0.037) for childhood HD, (but not for childhood NHL), was noted from 1975-
1995. In this study, annual average percentage increases or decreases of incidence 
rates were not reported, because such estimate was adequate provided the trend was 
relatively linear on the log scale. But reasons for the small declines in HD were not 
clear (Linet et al., 1999). 
 
Central Nervous System tumors 
Substantially increased trends of CNS tumors were observed in many countries over 
the last several decades, and there has been a consensus that these increases may be 
largely attributable to the diagnostic improvements in brain imaging (Magnani et al., 
2001b; Gurney et al., 1996; and Terracini et al., 2001). A study in the USA reported 
an increased incidence of childhood primary malignant brain tumors occurring in the 
mid-1980s. In this study, instead of assuming and testing a ‘linear model’ of the 
increasing trends of incidence rate of childhood cancers, a ‘jump model’ was 
introduced, i.e., a lower stable incidence rate before mid-1980s, and a higher constant 
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rate afterwards. This appropriately used model best explained the likely reason for 
increasing rates as being the greater use of improved diagnostic imaging technologies 
such as computerized tomography (CT) and magnetic resonance imaging (MRI) 
(Smith et al., 1998). A high incidence of brain tumors among children in Hungary 
between 1989 and 2001 was noted recently; the relative frequency of CNS tumors 
among childhood cancers during that period was higher than that in other European 
countries (Hauser et al., 2003). In England, annual increases of between 1-3% during 
1954–1998, were found in childhood brain tumors of pilocytic astrocytoma, primitive 
neuroectodermal tumors, and other types of gliomas. The pattern of increasing rates 
specific to certain cancer group and stable temporal trends pointed to the effects of 
some environmental risk factors other than infection (McNally et al., 2001b). A 
hospital-based study in Seoul, Korea, found that the relative incidences of brain germ 
cell tumors, neuronal tumors, and oligodendroglial tumors increased after the 
introduction of MRI, but that of medulloblastomas and ependymal tumors decreased 
during 1959-2000 (Cho et al., 2002).  
 
Other childhood cancers 
Honjo et al. (2003) investigated the trends in incidence and mortality rates of 
neuroblastoma in Osaka, Japan, from before and after a nationwide mass-screening 
program in 1985. They used Great Britain as a control because there was no 
difference in incidence between the two countries before the mass-screening program. 
The result after the screening showed an immediate increase in incidence rate for 
Osaka and it remained high for more than 5 years. The higher numbers were largely 
due to the increasing incidence among children less than 5 years old. Age-
standardized mortality rates per million were unchanged in Osaka and in Great Britain 
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and their study suggested that screening programs did not help to reduce the mortality 
rates and provide benefits.  A similar conclusion was drawn from a 5-year follow-up 
study after an infant screening program of neuroblastomas in Quebec, Canada (Woods 
et al., 2002). The incidence and mortality rates were compared with infants in 
unscreened places and the results showed that the screening program produced 
evidence of increased incidence rates of neuroblastomas but did not help in reducing 
the mortality rates (Woods et al., 2002).  
Lee et al (2003) in Taiwan compared the mortality rates (1974-1999) caused by 
childhood hepatocellular cancer before and after 1984, when a large-scale program of 
hepatitis B vaccination of newborns began. They found that the vaccination of 
hepatitis B reduced the childhood hepatocellular cancers in both boys and girls from 
1984.  
 
Risk factors related to incidence of childhood cancers 
The etiologies of childhood cancers are mostly unknown. Compared to adult cancers, 
childhood cancers are less likely to be caused by environmental factors. The parental 
hereditary factors and the environmental exposures before conception, during 
pregnancy and postnatal periods are likely to be more significant causes for childhood 
cancers.  
 
Genetic risk factors 
Inheritable single gene mutations that cause childhood cancers are rare. 
Retinoblastoma and Wilm’s tumors are two best known examples. Retinoblastoma 
occurs when there are mutations that destroy both copies of the tumor suppressor 
retinoblastoma (Rb) gene. In the sporadically nonheritable cases, the random mutation 
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of the retinoblastoma gene occurs mainly in one retinoblast, hence it is usually 
unilateral. In inherited retinoblastomas where there is a germline mutation of one of 
the retinoblastoma gene, the chances of another mutation to inactivate the other Rb 
gene are high. Hence this occurs in multiple cells, causing multifocal and bilateral 
retinoblastoma. 
 As for Wilm’s tumor, there also is a genetic basis. At least three genes: WT1 gene at 
chromosome 11p13 (Rainier & Feinberg, 1994), IGF2 and H19 genes at 11p15.5 
(Barlow, 1995) are involved in the development of tumor.  
However, for most types of childhood cancer, it was hard to decide which specific 
genes played roles on the etiology of cancer and how. ALL attracted lots of attention 
in the etiology field because it was the most common cancer among children. With 
174 patients and 337 controls diagnosed during 1988-1998, Krajinovic et al (2002) 
investigated whether the xenobiotics-metabolism enzymes CYP2E1, MPO and NQO1 
represented risk-modifying factors in childhood ALL. They found carriers of the 
CYP2E1*5 variant had 2.8-fold higher risk of developingALL (95%CI: 1.2-6.4) than 
non-carriers, and NQO1 alleles *2 and *3 contributed to the risk of ALL as well (OR 
= 1.7, 95%CI: 1.2-2.4).  The study suggested that the increased risk of ALL may be 
associated with altered xenobiotics metabolism and DNA repair. Klumb et al. (2003) 
reported in TP53 in childhood non-Hodgkin’s lymphoma patients, which was of 
prognostic significance. 
It is believed that no strong evidence of familial aggregation is apparent for the 
commoner types of childhood cancer, such as ALL. No definite excess of cancers in 
siblings, parents, and offsprings of patients with common childhood cancer was 
observed from the epidemiological studies (Little, 1999; Li et al., 1988). Nevertheless, 
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strong aggregation has been observed in patients with Li-Fraumeni syndrome in 
various geographic and ethnic groups (Li & Fraumeni, 1969).  
We further discuss the role of karyotypic abnormalities in childhood ALL since ALL 
accounts for around 3 quarters of leukemias (Little, 1999). Karyotypic abnormalities 
include numerical and/or structural abnormalities. From the numerical angle, 
karyotype of leukemic cell could be classified as normal diploid, pseudodiploid, 
hyperdiploid (≥47) or hypodiploid (<46) (van der Plas et al., 1992). From the 
structural angle, karyotypes abnormalities could also include translocations, such as 
11q23, t(9;22)(q34;q11) or del(22q), t(4;11)(q21;q23), t(11;19)(q23;p13), 
t(1;19)(q23;p13), t(8;14)(q24;q32), der(7;9)(q10;q10) and t(9;12)(q22;p11±12) 
(Forestior et al., 2000). There is no definite evidence to support that karyotypic 
abnormalities result in this disease though a recent research in Nordic countries 
doubted that del(9p) and/or del(6q) may play a primary role in leukemogenesis 
(Forestior et al., 2000). 
 
Race and age  
The notable incidence peak of childhood ALL was observed in children aged 1-4 
years in many studies (Draper et al., 1994; MaNally et al., 2001). This age peak in 
childhood ALL was less obvious and occurs later for US blacks than US whites 
(Gurney et al., 1996; Ross et al., 1994). McKinney et al. (2003) compared the 
incidence rate of childhood cancer between South-Asian children (one quarter of all 
the cases) and other Asian children from 1974-1997, and found the incidence rates of 
leukemia and ALL were marginally higher in South-Asian children than other 
children in Bradford, a city in the north of England. They also found that the Asian 
children had significantly higher risk of leukemia other than ALL (mostly AML). The 
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age-peak of incidence for South-Asian children at 5 to 9 years, was also different 
from white children which typically occurs between the ages of 2 to 5 years (Greaves 
et al., 1985). In an update study by SEER of childhood cancer from 1973-1998, the 
overall incidence rate in the US whites is 44% higher than that of US Blacks; the 
Hispanic subgroup had the highest incidence rate of all (McNeil et al., 2002). A role 
of genetic factors was suggested in ALL incidence for such features (Linet et al., 
2003). The incidence rates of childhood cancers for Chinese and Japanese immigrants 
to the US are much higher than the rates in their home countries (Parkin et al., 1992), 
which also implicated the effects of unknown exogenous and environmental factors. 
Racial difference was also observed in sympathetic nervous system cancers, renal 
tumors, and Ewing’s sarcoma (Linet et al., 2003). 
 
Gender 
The incidence of ALL was approximately 20% higher for boys than girls younger 
than 15 years of age during 1990-95 in the SEER study (SEER 1999). More boys 
were found to be affected by leukemias and lymphomas than girls. Reasons are 
unknown for the male predominance in most childhood cancers, but clues of etiology 
included gender-specific exposures, hormone influences and gender-related genetic 
differences (Linet et al., 2003). In some genetic studies, mismatch repair genes 
provide a protective influence in girls but not in boys leading to gender differences in 
incidence rate of childhood leukemia. The CYP1A1*4 allele was found to reduce the 
risk by 80% for girl carriers compared to boys, which may help to explain the lower 
incidence of ALL in girls (Krajinovic et al., 1999). Another study also suggested that 
the reduced risk in girls due to the protective influence of some genes. A 
polymorphism in the APE gene involved in the base excision repair system might 
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increase risk among boys and reduce risk among girls. A mismatch repair gene 
HMLH1 was also associated with reduction of risk among girls (Infante-Rivard 2003).  
 
Environmental factors 
It is plausible that environmental factors contributed to the increase in cancer 
occurrence, though few exogenous agents have been shown to increase risk for 
childhood cancers. The environmental factor may interact with genetic factors at an 
early stage in the child’s life. 
Population mixing 
In exploring the etiology of certain types of childhood cancer, Law et al. (2003) used 
a population-based case-control study to test the hypotheses of etiology of leukemia 
and lymphoma. One hypothesis suggested by Kinlen (1995) was that non-immune 
children of relatively isolated life-style were at elevated risk of leukemia or 
lymphoma when exposed to some unknown infectious agents through population 
mixing. Another hypothesis developed by Greaves (1997) was that some delayed 
infection brought to the subject a secondary risk of mutation leading to ALL or NHL, 
provided there was some first mutation in-utero but not enough to trigger off the 
cancer. The second mutation might be brought by low level population mixing. The 
study by Law et al. (2003) included 3838 cases of childhood cancer registered in the 
UK (1991-1996), and 7669 controls. The subjects were divided into 3 groups of ALL, 
NHL and all other tumors; the volume of population mixing (proportion of population 
with a different address 1 year before the census) was divided into three groups of 
<10%, 10-90% and >90%; the diversity of population mixing was calculated 
separately for ‘all-age’ and ‘childhood’ population. The odds ratio of the ALL group 
was 1.37 (95%CI: 1.00-1.86) for the lowest category of all-age population mixing 
 15 
diversity, the odds ratio of the NHL group was 2.83 (95%CI: 1.15-7.00) for the lowest 
category of childhood mixing diversity. There was no significant OR observed of the 
other tumors group. This study does not support the hypothesis by Kinlen because no 
association between disease and high diversity of population mixing was observed. It 




Dockerty et al. (2001) conducted a case-control study in England and Wales of 
childhood cancers during 1968-1986 to evaluate the relationship between parental risk 
factors and childhood cancers.  The parental age was found to be a significant risk 
factor for the incidence of ALL, a significant increasing trend of risk was observed 
with parental aging, however, increasing parity was a protective factor in childhood 
ALL. (See Table 2)  
Cnattingius et al. (1995) looked into many maternal and prenatal risk factors for 
childhood acute lymphatic leukemia. The study was a population-based case-control 
study nested in the cohorts of nationwide Medical Birth Registry in Sweden from 
1973 to 1989. Altogether 613 cases were included in the study. 5 controls were 
matched to each case by sex and age. More than 10 factors were analyzed as potential 
risk factors. The results showed that parity, previous infertility, number of 
spontaneous abortions and delivery-related factors had no effects on the children’s 
risk of lymphatic leukemia. Down’s syndrome was a strong risk factor with the OR of 
20.0 (95%CI: 4.2-94.2); mothers’ delivery age (<20 years old) was a significant risk 
factor with the OR of 1.4 (95%CI: 0.99-2.1). Maternal disease in blood-forming 
organs, maternal renal and hypertensive diseases increased the overall risk of 
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lymphatic leukemia in children. This population-based study was very useful in 
finding risk factors and provided more evidence to clinical and health care researchers. 
 
Table 2. ORs of Parental risk factors to childhood leukemia, brain tumors 
Cnattingius, 1995  Dockerty, 2001 Linet, 1996 Maternal risk 
factors ALL (95%CI) *ML (95%CI)  ALL (95%CI) ANLL(95%CI) CNS 
tumors(95%CI) 
Age at delivery       
≤19 1.4 (0.99-2.1) 2.5 (1.1-6.0)  1.0 (0.8-1.2) 0.9 (0.5-1.7) 1.1 (0.7-1.6) 
20-24 1.0 (0.8-1.2) 1.2 (0.7-2.2)  0.9 (0.8-1.0) 0.9 (0.7-1.2) 1.0 (0.8-1.3) 
25-29 1.0 (ref. group) 1.0 (ref. group)  1.0 (ref. group) 1.0 (ref. group) 1.0 (ref. group) 
30-34 1.2 (0.9-1.5) 1.1 (0.6-2.1)  1.1 (0.9-1.3) 0.7 (0.4-1.0) 1.0 (0.8-1.3) 
≥35 1.0 (0.7-1.5) 1.1 (0.6-5.0)  2.0 (1.2-3.2) 3.1 (0.97-9.8) 1.3 (0.6-3.1) 
Parity       
1 1.0 (0.8-1.2) 1.1 (0.7-1.7)  1.0 (0.8-1.1) 0.8 (0.6-1.0)  
2 1.0(ref. group) 1.0(ref. group)  0.9 (0.8-1.1) 1.0 (0.7-1.4)  
3    0.8 (0.7-1.1) 1.3 (0.8-2.3)  
4 1.0 (0.7-1.5) 1.2 (0.5-2.8)  0.9 (0.6-1.3) 0.8 (0.4-1.7)  
≥5    0.7 (0.4-1.1) 1.1 (0.4-2.6)  
*ML: Myeloid Leukemia 
Parental occupational exposure seems to be a risk factor in childhood CNS tumors. 
Based on the diagnosed cases of astrocytoma and primitive neuroectodermal tumors 
(PNET) in US and Canada during 1986-1989, van Wijngaarden et al. (2003) found 
that there were moderately elevated risks of astrocytoma to children of fathers 
exposed to pesticides with ORs ranging from 1.4 (95%CI: 0.7-1.7) to 1.6 (95%CI: 
1.0-2.7), and maternal exposure to some pesticides with ORs ranging from 1.3 
(95%CI: 0.5-3.7) to 1.6 (95%CI: 0.9-2.7). There were no risks to children’s PNET. 
The results suggested uncertain risks due to parental occupational exposure of 
pesticides to children’s brain cancer. Increased risks in childhood brain tumors were 
found associated with maternal use of oral contraceptives, narcotics and penthrane 
before conception, neonatal distress and infections (Linet et al., 1996).  
 
Social-economic status 
In developing countries, boys who are unwell are more likely to reach a medical 
center to obtain medical care. The underlying social-economic level of the society and 
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its culture play important roles in influencing the high male-to-female ratio of cancer 
registration (Pearce & Parker, 2001). An increased incidence rates of all childhood 
leukemias combined in relation to high socioeconomic level have been reported in 
Britain, which was apparent in the age group of 0-4, and 5-9 years old children 
(Draper et al, 1991).A different conclusion indicated that there was no significant 
effect on ALL risk, in relation to social class, based on parental occupation (Dockerty 
et al., 2001). These controversial conclusions may be due to small number of cases in 
some analyses, but effects of environmental factors were also suggested.  
 
Survival of childhood cancers 
With the information available in systematic cancer registries, the analysis of survival 
rates in order to assess the effectiveness of treatment and health care of childhood 
cancers became possible. The age-standardized mortality rates for all childhood 
cancers in Singapore from 1950 to1989 were, along with New Zealand and Costa 
Rica, among the highest reported, (6-7.5/100,000 for boys, 5-6/100,000 for girls) 
(Table 3).  
The high mortality may be related to the comparative high incidence rates, to some 
extent, in some countries such as Costa Rica (Parkin et al., 1998). The incidence rates 
in Singapore were in the mid-level range compared to other countries, so the high 
mortality rates (1985-89) may not be related to the pattern of childhood cancers 
incidence, attention should be paid to random variation, treatment and management of 
childhood cancers.  
In European countries, an average decrease in mortality of more than 60% from 
childhood cancers was observed from mid-1960s onwards (Levi et al., 2001). 
Tremendous decline in mortality was also observed in most developed countries. The 
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decline in mortality, which was observed in young ages since the survival of several 
tumor types decreases with ages, can largely attribute to the development of effective 
multi-drug chemotherapy protocols, together with the introduction of various 
supportive measures to overcome toxicity, and improved diagnostic techniques. The 
declines in childhood cancer mortality are essentially attributable to improved 
management of the disease (Levi et al., 1995). 
Table 3. Age-standardized mortality rate (per million) (Levi et al., 1995) 
 Total  Leukemia  
1990-94 boys girls boys girls 
Italy 5.84 4.57 1.96 1.45 
UK 4.26 3.51 1.36 0.90 
Sweden 4.09 3.77 1.33 1.05 
Germany 4.05 3.42 1.29 0.86 
1985-89     
Singapore 6.53 6.07 3.07 2.58 
Hong Kong 4.67 4.91 1.68 1.42 
Japan 4.97 4.08 1.91 1.50 
USA 4.16 3.49 1.41 1.09 
New Zealand 6.69 5.32 2.76 1.84 
Costa Rica 6.76 5.37 2.99 2.21 
 
In the US, systematic estimates by SEER on incidence, mortality and survival rates 
for all cancers have been made available since the 1970s (Ries et al., 1999). A series 
of survival studies of childhood cancers were also produced by the EUROCARE 
database, which included data from 34 population-based registries in 17 European 
countries between 1978 and 1992. It is the first large systematic study of survival for 
childhood cancers in Europe and is especially useful for inter-country comparisons on 
treatment protocols and health care (Magnani et al., 2001a).The survival rates of 
childhood cancers were similar to Europe (except Eastern Europe) to those in the 
United States. The reasons were due partly in the fact that childhood cancers are 
generally responsive to therapy, and also that pediatric patients have similar access to 
those treatments (Gatta et al., 2001). 
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Leukemia 
The 5-year survival rate in European countries varied from 56% to 80% during 1985-
89, the weighted European mean was 72% (95%CI: 69-75%) (Coebergh et al., 2001). 
It was found that the higher survival rates were achieved in countries with better 
access to centralized diagnostic technologies and treatment protocols. The outcome 
from European countries were similar with that in the US, Canada and Australia. 
Marked improvement of childhood ALL survival (5-year survival rate: 61%-77%) 
was observed by SEER since the 1970s. They counted the credit to the improvement 
of treatment during that period of time (SEER, 1999). Although the 5-year relative 
survival rates of ALL increased from 39.9% in 1975-84 to 67.6% in 1985-94 in Osaka, 
Japan, the survival for many diagnostic groups in Osaka were lower compared with 
those reported in England, Wales and USA. The possible reason may be insufficient 
use of chemotherapy and centralization of treatments in specialized hospitals for the 
diagnosed cases in Osaka (Ajiki et al., 2004). In Italy, the 5-year survival rate for 
ALL improved from 24.7% in 1970s to 81.1% in 1990s and for ANLL from 0% to 
38.1% (Pastore et al., 2001b). From the increasing survival rates worldwide, it is 
suggested that better outcomes for leukemia are still achievable in the future. In order 
to evaluate health care’s influence on the survival rate, Valsecchi et al. (2004) 
conducted a multi-center retrospective survey of childhood cancer in eight national 
level hospitals from 1996 to 1999, in seven countries in Central America and the 
Caribbean. There were wide variations among countries for 3-year survival rates of 
ALL from 74.2% in Costa Rica to 61.7% in Cuba, Nicaragua, and even lower in 
countries with less health care resources. They came to the conclusion that the inter-
country difference of survival were partly due to varying levels or absence of quality 
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health care; those patients dropped-out and stopped treatment were taken as ‘Failure’ 
in the follow-up and gave unfavorable outcomes (Valsecchi et al., 2004). 
 
Lymphomas 
The 5-year survival rate for childhood NHL increased from 25.2% in 1970s to 67.7% 
in1990s in Italy (Pastore et al., 2001b). Similar results were observed in a study in 
Osaka, Japan. The 5-year survival rates increased from 43.2% in the 1980s to 66.0% 
in the 1990s (Ajiki et al., 2004). However, studies by SEER reported much higher 
survival for childhood NHL with the 5-year survival at 56% in the 1980s and 72% in 
the 1990s (SEER, 2005). The European weighted average survival rates for childhood 
HD and NHL cases in 1985-89 were high at 93% and 74%, and different rates were 
also observed among countries. There showed an increasing trend of survival rates for 
childhood lymphoma from EUROCARE database during 1978-1992 (Pastore et al., 
2001a). Improved chemotherapy protocols and availability of health care are believed 
to be the reason of higher survival in US and Europe. 
 
Central Nervous System Tumors 
The average 5-year cumulative survival in 1978-1989 in European countries was 53% 
for CNS tumors, 44% for primitive neuroectodermal tumor (PNET), and 60% for the 
glioma-related neoplasms. Reduced risk of death was observed in late 1980s 
compared with 1978-1981, but not in the years 1990-1992 (Magnani et al., 2001b). 
Different results among European countries may be the result of difference in 
treatment and clinical care. The 5-year survival rate in Italy for the overall central 
nervous system (CNS) tumors changed from 33.4% in 1970s to 75.9% in 1990s 
(Pastore et al., 2001b). From the perspective of treatment it was seen that the 
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treatment strategies for CNS tumors developed slowly in the last two to three decades. 
Generally progress in management of CNS tumors has been slow. Complete excision 
represents the most important determinant of outcome in solid tumors. Unfortunately 
the central nervous system being a very sensitive area, complete excision is often 
impossible. Radiotherapy is associated with severe long term side-effects and 
chemotherapy had not been very successful. 
 
Hepatic Tumors 
Survival of childhood hepatic tumors during 1978-1989 was reported in the 
EUROCARE II study. The 5-year survival was 36% (95%CI: 28-46%) with no 
difference between genders. Survival improved significantly during the study period. 
Compared to the period 1978-1981, the period 1982-1985 had a hazard ratio (HR) of 
0.57 (0.36-0.91), and the period 1986-1989 had the HR of 0.40 (0.23-0.61). But 
survival in hepatocellular carcinoma (HCC) was 20% (6-52%) lower and showed no 
improvement during the study period (Moller et al., 2001). The 5-year relative 
survival of liver tumor patients was 47% in Osaka, Japan (Ajiki et al., 2004). Of 
the109 cases of hepatic tumors in Taiwan diagnosed between 1988 and 1992, only 49 
cases were histologically proven. The overall 5-year survival rate for hepatic tumors 
was 19%. The 5-year survival rate of childhood HCC (n=28) was 17%, and that of 
childhood hepatoblastoma (HB) (n=17) was 47% (Lee & Ko, 1998). 
 
Other childhood cancers 
In Japan, the mass screening program of neuroblastoma in infants was believed to be 
the reason for an increase in its survival (Honjo et al., 2003). The reduced risk of 
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death for childhood neuroblastoma was also observed in another EUROCARE study 
from 1978-1992 (Spix et al., 2001).  
Malignant bone tumors are rare which accounted for about 5% of all childhood 
cancers. The estimated 5-year survival rate was 60% for malignant bone tumors in 
1985-89 in European countries. Steady increase was observed for the survival of 
Ewing’s sarcoma during 1978-89. For osteosarcoma, no further improvement of 
survival since 1985; substantial increase of survival rate was found during 1978-85 in 
the EUROCARE study (Stiller et al., 2001a). Another study in EUROCARE by Stiller 
et al. (2001b), showed that the age-standardized 5-year survival rate (1985-1989) was 
65% for childhood rhabdomyosarcoma, 68% for fibrosarcoma, 78% for other 
specified soft tissue sarcomas except Kaposi’s and 51% (37-65) for other unspecified 
soft-tissue sarcomas. Survival rates increased steadily throughout the 12-year study 
period for the overall soft-tissue sarcomas. Improvements of treatment and clinical 
care may contribute to the increasing survival for childhood cancers. 
 
Prognostic factors of survival 
Race as a possible prognostic factor was investigated by many studies. It was found 
by the CCG group in USA that black and Hispanic children had worse survival than 
white children while Asian children had better outcomes (Bhatia et al., 2002). 
African-American and Spanish surname children had significantly less favorable 
survival of B-precursor ALL than white children (Pollock et al., 2000). But we need 
to bear in mind that race may be confounded by other factors because it is closely 
related to socio- economic status and standard of medical care available. Given equal 
access to effective treatment regardless of race or ability to pay, black and white 
children with ALL can achieve same high survival rates, with 5-year survival rate of 
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86.3% (95%CI: 77.2-95.2) for black children and 85.0% (95%CI: 80.9-89.1) for white 
children (Pui et al., 2003). In a national population-based study in England and Wales 
during 1971-1990, patients lived in poorer districts were found to have lower survival 
rates compared with those in rich districts among 44 of 47 adult cancers, but 
significant socioeconomic differences were not seen in 11 childhood cancers. This 
striking contrast was likely because effective chemotherapy is available for many 
childhood malignancies, treatment is highly centralized in a small number of 
specialist centers, and recruitment into randomized trials is common (Coleman et al., 
2001). 
From the perspective of clinical regimen, age and white blood cells (WBC) count 
were considered powerful prognostic factor for children with B-precursor ALL. 
Poorer outcome was found for infants and adolescents (compared with children aged 
1-9 years) and with higher WBC count (>= 50,000/µl) in many studies (Pui & Crist, 
1994; Sather, 1986). In ALL, risk stratification is based on the presenting white cell 
count, sex, age and cytogenetics of the tumor cells (Lilleyman & Pinkerton, 1996). A 
retrospective analysis was performed to evaluate the prognostic factors of ALL in 
Japanese children between 1991 and 1995. The presence of Philadelphia chromosome, 
translocations associated with chromosome 11q23, an acute unclassified leukemia, 
mixed-lineage leukemia, WBC counts at diagnosis above 100,000/µl, and male 
gender were found to be unfavorable (Horibe et al., 2000). Age less than 1 year and 
WBC more than 50,000/µl at diagnosis were negative prognostic factors for ALL 
(Viscomi et al., 2003). Lately efforts have been concentrated on the stratification of 
patients by risk factors which may avoid over treatment of good risk patients and limit 
dose escalation strategies. A more aggressive therapy, which is more toxic, should be 
applied to the higher risk patients to increase the survival.  
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Prognosis for neuroblastomas is dependent on age, stage of disease, and the molecular 
biologic and cytogenetic characteristics of the tumor (Brodeur & Castleberry, 1997). 
Age less than 1 year was a favorable prognostic factor for neuroblastoma in 2,678 
cases from the childhood cancer registry of Piedmont from 1970 to 1998 (Viscomi et 
al., 2003).  
No sex or racial preponderance was found in a hospital-based cohort study conducted 
on 38 pediatric patients with extracranial germ cell tumor from 1989 to 1999. The 
overall and event-free survivals at 10 years for the patients were 96% and 88%, 
respectively. The high survival rate may be due to the majority of patients presenting 


















With the implementation of population-based cancer registry in most developed 
countries, description of incidence rate and survival rate for childhood cancers is now 
possible. Inter-countries comparison of incidence and survival patterns of childhood 
cancers is of great interest by researchers. Higher incidence rates were observed in 
studies where cancer registries are more comprehensive and complete. Increasing 
trend of incidence for childhood cancers was observed over the last several decades in 
studies worldwide. It was believed to be contributed by improvement of diagnostic 
technologies and cancer ascertainment. However, the etiology of childhood cancers is 
complicated and no obvious factors have yet been confirmed. The survival rates have 
improved substantially for most childhood cancers over the last several decades. The 
advancement in treatment and increased accessibility to health care have undoubtedly 
contributed to the improvement.  
A nationwide cancer registry has existed for over thirty years in Singapore, yet no 
systematic studies on trends of incidence and survival rates for childhood cancers 
have been conducted. In this study, we will describe the incidence, trends of incidence 






In the following study, we describe the incidence and survival rates of childhood 
cancers from 1968 to 1997 in Singapore, and identify the trends of incidence and 
survival over the three decades. 
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Chapter 3   Materials and Methods 
Study subjects 
The childhood cancer data were retrieved from the nationwide Singapore Cancer 
Registry which has included all cases of cancer diagnosed in Singapore from 1968 
and onward (citizens and permanent residents).  
Cancer registrations are based primarily on notifications received from all sections of 
the medical profession in Singapore. The individually unique National Registration 
Identity Card (NRIC) number linked records from different sources. The Registry 
ensures that registrations are as complete as possible by routinely checking pathology 
records (biopsies and necropsies), hospital discharge records and death certificates. 
Information available for each patient included NRIC number, sex, race, date of birth, 
date of diagnosis, topographic and morphologic code, date of death (if death had 
occurred) and data related to previous cancers. The death registry was the only source 
of follow-up information of cases.  
Altogether 2129 cases (aged less than 15) of childhood cancers between 1968 and 
1997 were included in this study. As classification of childhood cancers were based 
on morphological diagnosis, the Manual of Tumor Nomenclature and Coding 
(MOTNAC) and the International Classification of Diseases for Oncology (ICD-O) 
were used to assign a morphological code for each case: MOTNAC for cases 
diagnosed 1968-92; ICD-O for cases diagnosed 1993-97. A classification system 
based on the morphology section of the International Classification of Childhood 
Cancer (ICCC) for childhood cancers is widely accepted and has been used in various 
reports from different countries. The incidences and survival rates can then be easily 
and efficiently compared with corresponding figures from other countries. All cases 
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were classified into 12 diagnostic groups according to the ICCC based on the 
histology of the cancer. (Kramarova & Stiller, 1996) 
 
Statistical Analyses 
For each group and sub-group of childhood cancers, age-, and sex-specific number of 
cases, relative frequency and rates were calculated. The relative frequency was 
calculated as the percentage contribution of each particular group or subgroup to the 
total cases for the period 1968 to 1997.  The patients were grouped according to sex 
(male and female) and age-groups (0, 1 to 4 years, 5 to 9 years, and 10 to 14 years). 
The incidence rates were calculated by dividing the number of cases collected during 
that period by the total population at risk during the same period. The frequency 
distribution was calculated by dividing the observed number of patients in the age and 
sex category concerned by the total number of pediatric patients with cancer (as a 
percentage). The entire population of eligible children was considered, with no 
selection for race.  
 
Incidence Analysis 
The average percentage of cases with microscopic verification of diagnosis (MV %) 
in our study cases was 86.9%. Number of cases, sex ratio, and relative frequency were 
calculated. Crude incidence rates are the ratio of the number of cases of a specified 
age-sex group and a corresponding (age-, sex-specific) population at risk and 
expressed as per million children per year. Age-standardized rates (ASR) are 
calculated by the direct method, using the world standard population for the age-
groups under 15 years provided by IARC (Parkin et al., 1998). The cumulative rate 
(Day, 1982) is the sum over each year of age of the age-specific incidence rates from 
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0 to 14 years’ age. The formula for cumulative rate is Cum.= r0+(4×r1)+(5×r2)+(5×r3), 
where r0, r1, r2 and r3 denotes the age-specific rates of children in age 0, 1-4, 5-9 and 
10-14 groups. It is expressed by per million.  Standardized rate ratio (SRR), 
ASR1/ASR2, was calculated to compare the differences of incidence rates of Chinese, 
Malay and Indian children for all childhood cancers and leukemia. 95% confidence 
interval (CI) was obtained by the following formula (Smith, 1987):  
(ASR1/ASR2) 1± (Zα/2/X), 
Where X= (ASR1 – ASR2)/√ (s.e. (ASR1)2+ (ASR2)2 
and Zα/2=1.96(at the 95% level). 
 
Survival Analysis 
63 cases (3 % of total cases) were diagnosed by necropsy; these were excluded for 
survival analysis. In this study, traditional cohort analysis was used to calculate the 
survival rates. Follow-up information of vital status was related to Singapore Death 
Registry with children whose death was reported or not. Cumulative relative survival 
rate (RSR) was presented for overall and some site-specific survival estimate. The 
age-specific expected survival were estimated using published age-, gender-, calendar 
year- and ethnic-specific mortality rates of the general population in Singapore 
(Registrar-General of birth and death; Year book of statistics). RSR is the ratio of the 
observed survival rate over a specific time interval to the expected (life-table) survival 
rate. The expected survival rates (ESR) were calculated using the published age-, 
gender-, calendar year- and ethnic-specific mortality rates of the Singapore general 
population. The cumulative RSRs and ESRs were estimated with Hakulinen method 
(Hakulinen, 1982). Standard errors (SEs) of survival rates were calculated by 
Greenwood’s method (Parmar & Machin, 1995). Confidence intervals of age specific 
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proportions (with limits between 0 and 100) were calculated by the formula p± 
Zα/2SE(p), where p is the estimated cumulative RSR, SE(p) the associated standard 
error, and Zα/2 the upper (/lower) α/2 percentage point of the standard normal 
distribution.  
The sex-, age-(0, 1-4, 5-9, 10-14 years), and calendar year-specific cumulative 
relative survival rates were calculated. Trends in survival were analyzed by the ten 
year period between 1968 and 1997. The survival analysis is calculated using the 
program of SURV2 developed by Finnish Cancer Registry (Voutilanen et al., 1998) 


















Chapter 4   Results 
Age and ethnic pattern 
Age, sex and race distribution of the study population is given in Table 2. Altogether 
2129 children were diagnosed with childhood cancers in Singapore from 1968 to 1997. 
There were 1168 boys (54.9%) and 961 girls (45.1%). Of the 2129 cases studied, 
42.6% (n=907) were younger than 5 years, 28.0% (n=596) were between 5-9 years 
and 29.4% (n=626) between 10-14 years old (Table 4).  
Table 4. Number and percentage of main childhood cancers by sex, age, race, and calendar 
years 
 Male  Female  Total 
 No. %  No. %  No. % 
Age         
<1 101 8.7  91 9.5  192 9.0 
1-4 402 34.4  313 32.6  715 33.6 
5-9 341 29.2  255 26.5  596 28.0 
10-14 324 27.7  302 31.4  626 29.4 
Total 1168 54.9  961 45.1  2129 100 
         
Race         
Chinese 880 75.3  747 77.7  1627 76.4 
Malay 194 16.6  161 16.8  355 16.7 
Indian 76 6.5  44 4.6  120 5.6 
others 18 1.5  9 0.9  27 1.3 
Total  1168 54.9  961 45.1  2129 100 
         
Cancer type         
I. Leukemia 470 40.2  343 35.7  813 38.2 
II. Lymphoma 139 11.9  69 7.2  208 9.8 
III. CNS tumors 160 13.7  143 14.9  303 14.2 
IV. Sympathetic NS tumors 55 4.7  49 5.1  104 4.9 
V. Retinoblastoma 36 3.1  35 3.6  71 3.3 
VI. Renal tumors 38 3.3  27 2.8  65 3.1 
VII. Hepatic tumors 23 2.0  12 1.3  35 1.6 
VIII. Malignant bone tumors 39 3.3  47 4.9  86 4.0 
IX. Soft tissue sarcomas 50 4.3  62 6.5  112 5.3 
X. Germ cell & gonadal neoplasms 56 4.8  64 6.7  120 5.6 
XI. Carcinomas and epithelial 
neoplasms 52 4.5 
 69 7.2  121 5.7 
XII. Other & unspecified 
neoplasms 50 4.3 
 41 4.3  91 4.3 
Total 1168 54.9  961 45.1  2129 100 
         
Year of diagnosis         
1968-1977 397 34.0  305 31.7  702 33.0 
1978-1987 336 28.8  291 30.3  627 29.5 
1988-1997 435 37.2  365 38.0  800 37.6 
Total 1168 54.9  961 45.1  2129 100 
 
Chinese was the majority (76.4%) race with 1627 cases, Malay was second with 355 
cases (16.7%), Indians were third with 120 cases (5.6%) and 27 cases of other races 
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comprised the remaining 1.3%. The three most commonly diagnosed childhood 
cancers over the 30 years were childhood leukemia (38.2%), CNS tumors (14.2%) 
and childhood lymphomas (9.8%). Hepatic tumors were the rarest cancers of all 
(1.6%). Overall, the number of cancer cases followed an increasing trend from 1968-
77 to 1988-97, except for a slight decrease in 1978-87. The changes in trend were 
observed to be the same for both boys and girls. 
 
Incidence  
In Appendix 1, age-, cancer type-specific cases and incidence rates, M/F ratio, relative 
frequencies, and MV% were presented. In Appendix 2, sex-, cancer type-specific 
cases and incidence rates are displayed. Trends of incidence estimated for childhood 
cancers in three decades were showed in Table 5.  
Table 5. Sex-, Site-specific age-standardized incidence rates (ASRs) for three decades       
















Leukemia 46.8 41.7 53.3  36.3 32.8 42.5  41.7 37.4 48.2 
Lymphoma 14.1 12.0 13.0  7.0 8.0 6.7  10.6 10.1 10.0 
CNS tumors 10.9 12.6 22.2  10.4 16.0 18.4  10.6 14.3 20.4 
Sympathetic NS 
tumors 5.1 7.8 6.0  5.2 4.8 6.8  5.2 6.4 6.3 
Retinoblastoma 2.5 3.8 6.1  3.7 4.9 4.7  3.1 4.3 5.5 
Renal tumors 3. 8 4.9 4.1  4.3 2.4 3. 3  4.0 3.7 3.7 
Hepatic tumors 1.7 1.7 3.7  1.1 1.6 1.6  1.4 1.7 2.7 
Malignant bone 
tumors 3.2 4.6 1.9  4.1 5.7 3.7  3.6 5.1 2.8 
Soft tissue 
sarcomas 5.2 4.4 4.9  3.4 9.2 6.9  4.3 6.7 5.8 
Germ cell & 








5. 5 3.8 5.7  4.8 1.9 6.2  5.1 2.9 6.0 







Figure 1. Male, age-standardized rates of all childhood cancers in three decade 1968-


























































Figure 2. Female, age-standardized rates of all childhood cancers in three decades 


































































The age-standardized rate (ASR) of leukemia (42.7 per million children per year) was 
highest among all groups of childhood cancers. Of the leukemia group, lymphoid 
leukemia (LL) accounted for 68.5% (n=557). The ASR of LL was the highest among 
subgroups of leukemia. Boys with LL had a 29.4% higher ASR (33.0) than that of 














































(21.3% of all leukemia). The ASR was 25.3% higher for boys (9.9) than for girls (7.9). 
Chronic myeloid leukemia (CML) accounted for only 4.9% of leukemia cases. The 
ASRs for CML were 2.4 for boys and 1.5 for girls. The peak incidence occurred at 0-
4 years of age for LL and ANLL but at 10-14 years of age for CML. The incidence 
rates for total leukemia increased from 41.7 in 1968-77 to 48.2 in 1978-87, except for 
a slight decrease in the second decade (37.4). Despite boys having higher rates than 
girls throughout the decades, they follow a consistent trend of increase after an initial 









Figure 4. Sex-specific age-standardized incidence rates (ASRs) of Leukemia for three decades 
 
Lymphoma 
The overall ASR of lymphomas was 10.2 per million children per year. There were 
more boys than girls affected by lymphoma, with M/F ratio of Hodgkin’s disease (HD) 
at 2.7, non-Hodgkin lymphoma (NHL) at 1.7, and an especially high ratio for 
Burkitt’s lymphoma at 4.5. The peak incidence of lymphomas was at age of 5-14 
































Cases of NHL accounted for 54.8% of lymphomas and its ASR was 5.6 per million 
children per year. The boys had 48.9% higher ASR (6.7) than girls (4.5). For HD, 











Figure 5. Sex-specific age-standardized incidence rates (ASRs) of Lymphoma for three decades 
 
Although boys had higher incidence rates than girls through the 30 years, the ASR has 
not changed much for both genders. The overall ASRs were 10.6, 10.1, and 10.0 for 
the years 1968-77, 1978-87, and 1988-97. 
 
Brain and spinal neoplasms 
Boys and girls had similar numbers of these cases; the overall M/F ratio was 1.1. The 
ASR was 15 per million children per year for all subgroups of CNS tumors combined.  
Astrocytoma was the most commonly diagnosed subtype of CNS tumors, and 
accounted for 34.3% of all cases. The boys had 8% lower ASR (4.9) than girls (5.3), 
and the M/F ratio was 1 in this group. The peak incidence occurred at 5-9 years of age 
for boys and at 5-14 years for girls. Primitive neuroectodermal tumor (PNET) 



































M/F ratio at 1.2. The ASR of boys (4.2) was 11% higher than that of girls (3.8). The 
peak incidence age was at 5-9 years. Ependymoma only accounted for 9.2% of all 
CNS tumors, its ASR was 1.5. Girls had 23% higher ASR (1.6) than boys (1.3). Their 
incidence occurred uniformly in the 3 age groups. During the 30 years, the incidence 
rates showed an increasing trend in both boys and girls. The overall ASR was 10.6, 












Figure 6. Sex-specific age-standardized incidence rates (ASRs) of CNS tumors for three decades 
 
Sympathetic nervous system tumors 
There were 104 cases of sympathetic nervous system tumors, which accounted for 
4.9% of all childhood cancers. The majority of this group were neuroblastomas 
(n=95). Boys had 20% higher ASR (6.0) than girls (5.0), and their M/F ratio was 1.3. 
The peak incidence occurred at 0-4 years of age.  
The sex-specific ASR had not changed much over the 30 years for both boys and girls. 
The overall ASRs were 5.2, 6.4 and 6.3 per million children per year for years 1968-

































Retinoblastoma accounted for 3.3% of all cases (n=71). Boys and girls had similar 
risk, the overall ASR was 4.3. The M/F ratio was 1. The peak incidence age was 1-4 
years for both genders.  
The sex-specific ASR for boys increased slightly, with 2.5 per million children per 
year in 1968-77, 3.8 in 1978-87, to 6.1 in 1988-97 but the ASRs has not changed 










Figure 7. Sex-specific age-standardized incidence rates (ASRs) of retinoblastoma for three decades 
 
Renal tumors 
Of the 65 cases of renal tumors, 87.7% were Wilms’ tumors (n=57). The ASR for all 
renal tumors was 3.8. Boys had 31% higher ASR (3.8) than girls (2.9) of Wilms’ 
tumor, and the M/F ratio was 1.5. The ASRs of renal tumors remained consistent 
through the thirty years, at 4.0 in 1968-77, 3.7 per million children per year in 1978-



































Hepatic cancers were the least commonly diagnosed accounting only for 1.6% of all 
childhood cancers. The overall ASR was 1.9 per million children per year. The major 
subtype was hepatoblastoma (68.6%). Boys had 33% higher ASR (1.6) for 
hepatoblastoma than girls (1.2), and more boys were diagnosed than girls with the 
M/F ratio at 1.5.  
The sex-specific ASRs of boys were higher than those of girls through the 30 years. 
Both of them had an increasing trend, and the overall ASRs were 1.4, 1.7 and 2.7 per 
million children per year in the three decades respectively.  
 
Malignant bone tumors 
86 children were morphologically confirmed to have malignant bone tumors 
(MV%=100%). Fewer boys were diagnosed than girls with malignant bone tumors 
except for Ewing’s sarcoma (4:1). The overall M/F ratio was 0.8. The overall ASR 
was 3.8 per million children per year. 73.3% of the cases (n=63) were osteosarcoma, 
the commonest subtype. Girls had 50% higher ASR (3.3) than boys (2.2). The M/F 
ratio was also 0.8. The peak age of incidence was 10-14 years old for both genders. 
The sex-, calendar year-specific ASR of malignant bone tumors increased in year 
1978-87 compared with the previous ten years and then decreased in 1988-97 for both 
boys and girls. The overall ASRs were 3.6, 5.1 and 2.8 per million children per year 













Figure 8. Sex-specific age-standardized incidence rates (ASRs) of malignant bone tumors for three 
decades 
 
Soft tissue sarcomas 
Soft tissue sarcomas were the sixth most commonly diagnosed among all cancers, 
accounting for 5.3% (n=112). The ASR for all cases was 5.5 per million children per 
year. Rhabdomyosarcoma accounted for more cases than other subtypes, accounting 
for 48.2% of all. There were slightly more boys than girls diagnosed with this type, 
the M/F ratio of 1.2. The boys and girls had similar ASR of 2.9 and 2.7. Fibrosarcoma 
was the second most common subtype (24.1%). Fewer boys than girls were diagnosed 
in this group and the corresponding M/F ratio was 0.6. The boys had 78% lower ASR 
(0.9) than girls (1.6).  There were no cases diagnosed with Kaposi’s sarcoma. 
For boys, the ASRs decreased from 5.2 in 1968-77 to 4.4 in 1978-87, and then 
increased a little to 4.9 in 1988-97 which was still lower than that in the first ten years. 
For girls, the ASRs increased from 3.4 in 1968-77 to 9.2 in 1978-87 and then dropped 
slightly to 6.9 per million children per year in year 1988-97 which is still much higher 
































Germ cell and gonadal neoplasms 
Germ cell and gonadal neoplasms, the fifth most commonly diagnosed cancer (n=120), 
accounted for 5.6% of all childhood cancers. The overall ASR was 6.2 per million 
children per year. The most common subtype was ‘gonadal germ cell tumors’ 
accounting for 38.3% of all germ cell neoplasms (n=46). The M/F ratio was 0.6. Girls 
had higher risk than boys, with ASRs 2.7 and 1.9, respectively. The peak age of 
incidence was 0-5 for boys but 10-14 for girls. The second most common subtype was 
‘gonadal carcinoma’ at 26.7% (n=32). Boys had higher ASR (2.6) of gonadal 
carcinoma than girls (0.9) and the M/F ratio was 2.2. The peak incidence was at age 















Figure 9. Sex-specific age-standardized incidence rates (ASRs) of germ cell and gonadal neoplasms for 
three decades 
 
For boys, the sex-, calendar year-specific ASRs increased markedly from 2.5 in 1968-
77, to 5.0 in 1978-87 to 10.7 per million children per year in 1988-97. For girls, the 
ASRs decreased slightly from 4.7 in 1968-77 to 3.2 per million children per year in 


































Carcinomas and epithelial neoplasms 
The carcinomas and epithelial neoplasms were the fourth most commonly diagnosed 
group of cancer at 5.7% of all cases (n=121). The peak age of incidence was 10-14 
years old for all subgroups. The overall ASR was 5.4 per million children per year.  
Thyroid carcinomas accounted for 31.4% of all cases in this subgroup. Girls had a 
higher incidence rate (2.5 per million children per year) than boys (0.8) and more 
cases (M/F=0.3). Nasopharyngeal carcinomas accounted for 19% of all cases. Most of 
the cases were boys and less than 5 were girls. The ASR for boys was 1.6 for 
nasopharyngeal carcinomas. 
For boys, the ASRs had decreased from 5.9 in 1968-77 to 5.4 in 1978-87 to 2.0 per 
million children per year in 1988-97 whereas those for girls rose from 4.2 in 1968-77 
to 6.9 in 1978-87 and then to 7.6 per million children per year in 1988-97. 
 
Ethnic difference of incidence 
Of all the cases, Chinese children accounted for 75.3% (n=1627), Malay children 
16.6% (n=355) and Indian children 6.5% (n=120). Due to the limited number in most 
groups, racial differences were conducted for all cancers and leukemia. From 1968 to 
1997, the ASRs of all childhood cancers was 112.3 per million for Chinese children, 
103.9 per million for Malay children and 89.5 per million for Indian children. While 
the ASRs of Leukemia was 43.8 per million for Chinese children, 41.2 per million for 
Malay children and 36.9 per million for Indian children.  Standardized rate ratio (SRR) 
was calculated for each pair of racial groups. Significantly elevated risk was observed 
for Chinese children when compared to Malay and Indian children with childhood 
cancers, or with leukemia (Table 6). The relative risk of childhood cancers in Chinese 
children was 1.08 (95%CI: 1.04-1.12) when compared with Malay children, and 1.25 
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(95%CI: 1.19-1.33) with Indian children. Chinese children also had higher risk of 
leukemia than Malay (SRR: 1.06, 95%CI: 1.00-1.12) and Indian children (SRR: 1.19, 
95%CI: 1.09-1.30). The Indian children had the lowest risk of childhood cancers or 
leukemia. The SRRs for all Childhood cancers and leukemia showed only little 
elevated risks among ethnic groups, though the SRR was slightly higher for all 
childhood cancers compared with leukemia in correspondent ethnic-specific 
comparisons. The elevated risks for all childhood cancers may be partly contributed 
by those for leukemia. 
Table 6 Race-specific ASR for Chinese, Malay and Indian children, and ethnic 
pairwise comparison 







Total Chinese 1627 112.3 CN-MY 1.08 1.04-1.12 
 Malay 355 103.9 MY-IN 1.16 1.09-1.24 
 India 120 89.5 CN-IN 1.25 1.19-1.33 
Leukemia       
 Chinese 616 43.8 CN-MY 1.06 1.00-1.12 
 Malay 141 41.2 MY-IN 1.12 1.01-1.37 
 India 49 36.9 CN-IN 1.19 1.09-1.30 
 
Survival 
Altogether 2066 cases were suitable for survival analysis. The relative survival rates 
for childhood cancers have increased steadily since 1968 to 1997. The 5-year survival 
rates increased from 32.8% (95%CI: 29.3-36.6) in 1968-1977, to 45.3% (95%CI: 
41.5-49.3) in 1978-1987; and to 57.0% (95%CI: 53.2-60.7) in 1988-1997. The 5-year 
survival rate increased 73.8% over the thirty years. The results were shown in table 7. 
Table 7. The 1-, 3-, 5, 7-, 10-year specific relative survival rates for all childhood 
cancers of 3 decades and total 
 N* 1 year 3 years 5 years 7 years 10 years 
  RSR(95% CI) RSR(95% CI) RSR(95% CI) RSR(95% CI) RSR(95% CI) 
1968-67 326 49.8 (45.9-53.6) 36.7 (33.0-40.5) 32.8 (29.3-36.6) 31.8 (28.3-35.5) 31.0 (27.6-34.7) 
1978-87 203 67.3 (63.5-70.9) 50.2 (46.2-54.1) 45.3 (41.5-49.3) 43.7 (39.9-47.7) 42.5 (38.7-46.4) 
1988-97 190 75.3 (72.1-78.2) 61.3 (57.7-64.8) 57.0 (53.2-60.7) 52.3 (48.2-56.4) 48.9 (44.1-53.6) 
1968-97 719 64.7 (62.6-66.8) 49.9 (47.7-52.1) 45.4 (43.2-47.6) 43.2 (41.0-45.5) 41.8 (39.6-44.1) 
*N: the number of patients still alive at the beginning of the interval. 
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Trends of survival for selected childhood cancers over the three decades are showed 
in figure 1. Increasing trend was observed in ALL, ANLL, NHL, CNS tumors, renal 
tumors and germ cell tumor; while for neuroblastoma, osteosarcoma and soft tissue 
sarcoma, no obvious trends were showed. Details of each group of cancer were 



















Figure 10. Trends of cumulative RSRs for five childhood cancers over the three decades 
 
Lymphoid Leukemia 
The overall survival was 41.9% (95% CI: 37.6-46.3) for children ALL 5 years after 
diagnosis. It increased substantially from 24.8% (95% CI: 18.7-32.0) in 1968-77, to 
40.4% (95% CI: 33.2-48.2) in 1978-87, to 58.2% (95% CI: 50.8-65.2) in 1988-97. 
There showed little difference of survival between boys (41.4%, 95% CI: 35.8-47.2) 
and girls (42.7%, 95% CI: 36.1-49.5). The children of 1-4 years’ age had the best 
survival of 49.1% (95% CI: 42.4-55.8), followed by children of 5-9 years of 48.9% 
(95% CI: 41.2-56.7), the infants and 10-14 years old children had the worse survival 






























Acute Non-lymphocytic Leukemia 
The overall survival rate was 21.9% (95% CI: 15.9-29.3) for ANLL 5 years after 
diagnosis. The survival rates declined from 21.9% (95% CI: 13.5-33.5) in 1968-77 to 
11.9% (95% CI: 5.2-25.0) in 1978-87, then increased to 31.3% (95% CI: 19.2-46.8) in 
1988-97. The 5-year survival for girls (24.1%, 95% CI: 14.9-36.6) was slightly better 
than boys (20.4%, 95% CI: 13.3-30.1). The 5-year survival was highest in infants 
(28.9%, 95% CI: 8.3-64.7), and lowest in children aged 10-14 years (13.0%, 95% CI: 
5.7-26.7). 
 
Table 8. 5-year survival rates and 95% confidence interval for ALL, ANLL, NHL, 
CNS tumors by sex, age, and year differences 
 ALL ANLL NHL CNS tumors 
Sex 
N* 5-year survival 
(%) (95% CI) 
N 5-year survival 
(%) (95% CI) 
N 5-year survival 
(%) (95% CI) 
N 5-year survival 
(%) (95% CI) 
Male 120 41.4(35.8-47.2) 15 20.4(13.3-30.1) 26 42.6(31.5-54.6) 47 43.7(35.5-52.3) 
Female 84 42.7(36.1-49.5) 14 24.1(14.9-36.6) 13 35.5(22.5-51.0) 55 43.9(35.5-52.7) 
Years         
68-77 45 24.8(18.7-32.0) 14 21.9(13.5-33.5) 11 21.7(12.5-34.8) 28 38.4(27.7-50.3) 
78-87 75 40.4(33.2-48.2) 6 11.9(5.2-25.0) 13 40.7(25.6-57.8) 38 40.1(30.6-50.4) 
88-97 84 58.2(50.8-65.2) 9 31.3(19.2-46.8) 15 76.0(56.2-88.6) 36 49.9(40.2-59.7) 
Age         
0 5 22.1(10.2-41.7) 1 28.9(8.3-64.7) 2 33.9(9.9-71.3) 5 30.5(13.9-54.5) 
1-4 102 49.1(42.4-55.8) 10 23.2(13.8-36.5) 10 37.1(21.6-55.9) 20 45.4(32.9-58.5) 
5-9 77 48.9(41.2-56.7) 13 27.9(17.3-41.9) 11 41.3(26.3-58.2) 42 45.2(36.2-54.5) 
10-14 20 20.5(13.7-29.4) 5 13.0(5.7-26.7) 16 41.1(27.3-56.4) 35 44.0(33.4-55.2) 
Total 204 41.9(37.6-46.3) 29 21.9(15.9-29.3) 39 39.8(31.0-49.3) 102 43.7(37.8-49.9) 
*N: the number of patients still alive at the beginning of the interval. 
 
Non-Hodgkin’s Lymphoma 
The 5-year survival rates of NHL increased over the thirty years in Singapore children 
from 21.7% (95% CI: 12.5-34.8) in 1968-77, to 40.7% (95% CI: 25.6-57.8) in 1978-
87, to 76.0% (95% CI: 56.2-88.6) in 1988-97. The overall 5-year survival rate was 
39.8% (95% CI: 31.0-49.3). The boys had better survival (42.6%, 95% CI: 31.5-54.6) 
than girls (35.5%, 95% CI: 22.5-51.0). The children aged 5-9 and 10-14 had similarly 
survival rates of 41.3% (95% CI: 26.3-58.2) and 41.1% (95% CI: 27.3-56.4), which is 
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better than 37.1% (95% CI: 21.6-55.9) of children aged 1-4, followed by 33.9% of 
infants. 
 
Central Nervous System tumors 
For CNS tumors, the 5-year survival rates increased over the thirty years from 38.4% 
(95% CI: 27.7-50.3) in 1968-77, to 40.1% (95% CI: 30.6-50.4) in 1978-87, to 49.9% 
(95% CI: 40.2-59.7) in 1988-97. The overall survival rate was 43.7% (95% CI: 37.8-
49.9) at 5 years after diagnosis. The boys and girls had similar survival rates of 43.7% 
(95% CI: 35.5-52.3) and 43.9% (95% CI: 35.5-52.7). The most favorable outcome is 
45.4% (95% CI: 32.9-58.5) for children aged 1-4 and 45.2% (95% CI: 36.2-54.5) for 
children aged 5-9, the poorest outcome is 30.5% (95% CI: 13.9-54.5) for infants. 
 
Table 9. 5-year survival rates and 95% confidence interval for NB, Osteosarcoma, 
Renal tumors, Soft tissue sarcoma, and Germ cell tumors by sex, age, and year 
differences. 
 NB Osteosarcoma Renal tumors Soft tissue sarcoma Germ cell tumors 
Sex 
N 5-year survival 
(%) (95% CI) 
N 5-year survival 
(%) (95% CI) 
N 5-year survival 
(%) (95% CI) 
N 5-year survival 
(%) (95% CI) 
N 5-year survival 
(%) (95% CI) 
Male 15 40.3 (27.5-54.6) 5 19.8(8.8-38.6) 23 65.8(49.8-79.0) 24 56.0(41.8-69.3) 32 79.7 (67.0-88.5) 
Female 15 46.3 (31.2-62.1) 9 25.0(13.8-41.1) 17 69.9(50.7-84.1) 34 61.0(48.2-72.5) 30 68.3 (55.1-79.2) 
Years           
68-77 9 37.7 (21.3-57.6) 6 25.1 (12.0-45.0) 13 54.6(35.3-72.6) 14 45.0(28.5-62.7) 13 48.2 (30.1-66.8) 
78-87 14 45.4 (29.3-62.5) 7 27.0 (13.7-46.2) 14 74.0(51.4-88.6) 29 67.6(52.6-79.7) 16 64.2 (44.6-80.0) 
88-97 7 40.7 (23.8-60.1) 1 8.5 (1.5-35.9) 13 76.5(55.2-89.7) 15 59.4(42.5-74.4) 33 88.5 (77.9-94.5) 
Age           
0 17 76.8(57.1-89.5) / / 8 50.7(28.4-72.9) 5 64.4(32.2-87.8) 12 89.1(66.3-97.6) 
1-4 8 29.1(17.3-44.5) 1 33.4(6.2-79.4) 26 75.9(60.0-86.9) 10 40.8(24.6-59.4) 19  77.9(61.9-88.4) 
5-9 3 20.0(7.1-45.2) 3 25.7(9.2-54.1) 4 62.6(30.6-86.4) 18 58.1(40.8-73.7) 9 63.5(41.2-81.2) 
10-14 2 66.8(20.8-94.0) 10 21.3(12.0-35.0) 2 66.8(20.8-94.1) 25 70.4(54.9-82.4) 22 69.3(53.3-81.7) 
Total 30 42.8 (32.7-53.6) 14 22.8 (14.1-34.7) 40 67.5(55.3-77.8) 58 58.9(49.3-67.8) 62 73.8 (64.8-81.3) 
*N: the number of patients still alive at the beginning of the interval. 
 
Neuroblastoma 
The overall 5-year survival rate for children with neuroblastoma was 42.8%. The 
survival increased from 37.7% in 1968-77 to 45.4% in 1978-87, then declined a little 
to 40.7% in 1988-97. The girls had better survival (46.3%, 95% CI: 31.2-62.1) than 
boys (40.3%, 95% CI: 27.5-54.6). The infants had highest survival rate of 76.8 (95% 
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CI: 57.1-89.5), the children of 5-9 years’ age had the lowest survival rate of 20.0% 
(95% CI: 7.1-45.2). 
 
Osteosarcoma 
The overall 5-year survival rate was 22.8%. The girls had better survival (25.0%, 95% 
CI: 13.8-41.1) than the boys (19.8%, 95%CI: 8.8-38.6). 
 
Germ Cell Tumors 
The 5-year survival rates for the germ cell tumors increased from 48.2% (95% CI: 
30.1-66.8) in 1968-77, to 64.2% (95% CI: 44.6-80.0) in 1978-87, and 88.5% (95% CI: 
77.9-94.5) in 1988-97. The boys had better survival 5 years after diagnosis with 
79.7% (95% CI: 67.0-88.5) than the girls with 68.3% (95% CI: 55.1-79.2). The 
infants had most favorable survival with 89.1% (95% CI: 66.3-97.6), the children 
aged 5-9 years had poorest survival of 63.5% (95% CI: 41.2-81.2).  
 
Renal tumors 
The overall survival rate for children with renal tumors was 67.5% (95% CI: 55.3-
77.8) at 5 years after diagnosis. The 5-year survival rates increased from 54.6% (95% 
CI: 35.3-72.6) in 1968-77, to 74.0% (95% CI: 51.4-88.6) in 1978-87, to 76.5% (95% 
CI: 55.2-89.7) in 1988-97. The girls had slightly higher 5-year survival rate (69.9%, 
95% CI: 50.7-84.1) than the boys (65.8%, 95% CI: 49.8-79.0). The children of age 1-
4 years had the best outcome with 5-year survival rate of 75.9% (95% CI: 60.0-86.9), 




Soft tissue sarcomas 
The girls had slightly better survival (61.0%, 95%CI: 48.2-72.5) than the boys (56.0% 
95%CI: 41.8-69.3). The survival rates increased from 45.0% (95%CI: 28.5-62.7) in 
1968-77 to 67.6% (95%CI: 52.6-79.7), then decreased to 59.4% (95%CI: 42.5-74.4). 
The overall survival rate is 58.9% (95%CI: 49.3-67.8). The infants and children aged 
10-14 years had better survival rate, and the children aged 1-4 had the poorest 




















Chapter 5   Discussion: 
This study described the pattern of cancer incidence and survival rates among children 
in Singapore born from 1968 through 1997. To our knowledge, this is the largest 
population-based study in Asia describing the incidence rates and survival over a 
period of thirty years. This registry is considered complete and accurate based on 
multiple sources of data and well established systematic health care procedures in 
Singapore. To standardize the classification of childhood cancers, the two sets of 
codes (MOTNAC 1968-92 & ICD-O 1993-97) were recoded according to the codes 
used in ICCC. Unfortunately the MOTNAC and ICD-O codes have broader categories 
than ICCC. Where it was not possible to recode based on MOTNAC and ICD-O, the 
information of clinical diagnosis in the registry was used to help deciding which 
major group the case should be under. If all fails, this was group as ‘Unspecified’. 
Based on the source of verification for all cases, 86.9% of the diagnosis was 
histologically verified. Only 4.3% of patients were classified into ‘Other and 
Unspecified neoplasms’ category, which is similar to levels in Europe and US (Gatta 
et al., 2002). These features of data eliminate artificial errors and validate the 
reliability of our study. 3% of all cases (n=63) diagnosed by necropsy were also 
excluded from the survival analysis. Age-standardized incidence rates and sex-, age-, 
calendar year-specific relative survival rates make the outcomes comparable with 
those of studies in other countries. 
 
Incidence 
The cumulative rate is the sum of age-specific rates of each age group, where each 
age group age-specific rate is given the same weight. The cumulative rate is thus 
equivalent to an age-standardized rate. Based on reviewed journals and publication, 
 50 
ASR was most frequently used term to explain results. To allow comparison to other 
studies, we used the ASR for each of the cancer groups. Cumulative rates were only 
presented in tables following the standard format in International Incidence of 
Childhood Cancer by IARC (Parkin et al., 1988a, 1998). 
The incidence of childhood cancers varied a lot in the seventies and the eighties 
worldwide (Parkin et al., 1998). (Table 1, page 5) The overall age-standardized rate 
(ASR) of childhood cancers over the thirty years was 109.3 per million children per 
year for children aged 0-15 in our study (boys: 116.2 per million; girls: 101.5 per 
million). That means about 100 children in Singapore are diagnosed with cancer every 
year. This result was comparable with those of other western and Asian countries. 
(Table 1)   
Our study showed an increasing trend for most childhood cancers over thirty years, 
such as leukemia, CNS tumors, sympathetic nervous system tumors, retinoblastoma, 
hepatic tumors, and ‘germ cell and gonadal neoplasms’. Over the thirty years, the 
quality of health care in Singapore has improved dramatically, which means the 
decline of infective deaths and decrease in mislabeling of deaths linked infections due 
to depressed immunity from leukemia or dehydration due to vomiting in brain tumors. 
The improvements of diagnostics like trained personnel for full blood counts and bone 
marrow morphology and imaging like CT scan and MRI will undoubtedly improve 
the diagnosis of childhood cancers. 
From table 10, we can see that CNS tumors, followed by germ cell and gonadal 
neoplasms and leukemia which require much more intensive diagnostic techniques 
than other tumors as the incidence rates increased greatly over the three decades. 
Leukemia and CNS tumors alone accounted for up to 56% of the absolute increase in 
the incidence of childhood cancers. These may be accounted for by improvement in 
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diagnostic technology like MRI and CT scan and dedicated clinical management. 
Simple diagnostic investigations like intravenous urogram and ultrasound were used 
to diagnose renal tumors, sympathetic nervous tumors showed little or no increase for 
such conditions. Tumors which are not sensitive to diagnostic technology like 
lymphomas, bone and soft tissue sarcoma showed little increase because of their 
superficial nature or that only simple imaging is needed, which is already readily 
available in the late 1960s. 
Table 10.  Absolute change of incidence rates for childhood cancer from 1968 to 1997 
Childhood cancers 1968-77 1988-97 Absolute change from 1968-77 to 1988-97 
Leukemia 41.7 48.2 6.5 
Lymphoma 10.6 10.0 -0.6 
CNS tumors 10.6 20.4 9.8 
Sympathetic NS tumors 5.2 6.3 1.1 
Retinoblastoma 3.1 5.5 2.3 
Renal tumors 4.0 3.7 -0.3 
Hepatic tumors 1.4 2.7 1.3 
Malignant bone tumors 3.6 2.8 -0.8 
Soft tissue sarcomas 4.3 5.8 1.5 
Germ cell & gonadal 
neoplasms 3.6 11.0 7.4 
Carcinomas and epithelial 
neoplasms 5.1 4.7 -0.4 
Overall 98.3 127.0 28.7 
In this study, the incidence rates of leukemia declined a little from 1968-77 to 1978-
87, then increased sharply in 1988-97. Steady increase of leukemia incidence over 
long time periods have been reported in studies worldwide (Jakab et al., 2002; 
Magnani et al., 2003; McNeil et al, 2002; McNally et al., 2001a). Linet et al. (1999) 
reported no large changes of incidence of leukemia from 1975 to 1995 in SEER, 
despite a short-term increase in 1983-86 which was because of improvement of 
diagnosis occurred over 9 registries in the US. The overall marked increase in 
Singapore over thirty years in this study was thought to be due to the improvement of 
diagnostic techniques and enhanced access to health care with economic development 
nationwide. The reason for the slight decrease from 1968-77 to 1978-87 is not clear. 
The trend of incidence rates of leukemias in this study is for all types of leukemia 
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combined instead of trends of ALL, which makes the interpretation of trend difficult. 
Although the non-ALL leukemias accounts for only 31.5%, the changes of their 
incidence rates can influence the total trend. In SEER, The higher rate of nonspecific 
classification of leukemia cases  in the years prior to 1977 restricted examinations of 
trends for specific leukemia diagnosed from 1977 to 1995 (SEER, 1999). 
The incidence rate for NHL was 5.6 per million from 1968 to 1997 in this study. This 
estimate was lower than that of 9 per million in Sweden (Samuelsson et al., 1999) and 
8.4 per million in SEER (Gurney et al., 1996). The difference may be related to race. 
More detailed studies on race-specific incidence trends could be conducted to find the 
clues of low incidence here. Generally, boys are more affected with lymphomas than 
girls; the M/F ratio was 2.7 for HD, 1.7 for NHL and 4.5 for Burkitt’s lymphoma. The 
male predominance was also confirmed in other studies (McNally et al., 2001a; 
Samuelsson et al., 1999). The reason of high incidence for lymphomas among boys 
remains unclear. But also mirrors the similar male predominance in childhood ALL, 
another lymphoid cancer. 
There was no obvious variation in the incidence of lymphomas over the three decades 
in this study. There was only a slight decrease from10.6 in 1968-77 to 10.1 in 1978-87 
and to 10.0 in 1988-97. This result is consistent with the stable trends for both HD and 
NHL in 1974-91 by SEER (Gurney et al., 1996) and in UK between 1954 and 1988 
(Blair & Birth, 1994). But more recently, slight increase of lymphomas was reported 
(McNally et al., 2001a; Weidmann et al., 1999). The somewhat higher incidence of 
NHL in Sweden during 1975-94 than was reported in previous studies was thought to 
be due to thorough data collection and reexamination of source materials (Samuelsson 
et al., 1999). The different trends observed within the European study also suggested 
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an artificial effect leading to the temporal change of trend (McNally et al, 2001a). The 
stable trends in Singapore do not reflect these changes. 
The incidence of CNS tumors in this study showed a constant increase from 10.6 in 
1968-77 to 20.4 in 1988-97over the three decades in Singapore. Significant linear 
increase of all CNS tumors was also seen from 1954 to 1988 in North Western 
Regional Health Authority area of England, with an estimated increase of 7% per 5 
years (95% CI 4-11%) (Blair & Birth, 1994). In US, a higher constant rate of 
childhood CNS tumors occurring in the mid-1980s after a lower stable level was 
explained by the improved diagnostic technologies and changes in classification 
(Linet et al, 1999; Smith et al., 1998). So far there has been a consensus that these 
increases may be largely attributable to the diagnostic improvements in brain imaging 
(Magnani et al., 2001a; Gurney et al., 1996; and Terracini et al., 2001).  Due to the 
widespread use of computed tomography (CT) and magnetic resonance imager (MRI) 
in the 1980s in developed countries, more patients with CNS tumor could be detected 
and diagnosed. CT scan and MRI head have undoubtedly greatly changed the 
diagnosis and management of brain tumors. Apart from the improvement in 
diagnostic techniques, more refined ascertainment over time can also induce the 
artificial increases in CNS incidence rates in the study of registry data (Gurney et al., 
1996). In 1983, a CT scanner was utilized for the first time in a public hospital in 
Singapore. Several years later MRI scans were available to most Singaporeans.  
For brain and spinal neoplasms, the age group of 5-9 years was the peak age group for 
both genders in Singapore according to the overall data from the last 30 years. This 
phenomenon was also observed in a European study (Magnani et al., 2001a). 
However, it is different from the data shown in a report from the US. A SEER study 
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of US showed that 0-4 years was the peak age group for all childhood CNS tumors, 
followed by 5-9 years group (Gurney et al., 1996). The difference is not clear. 
 
This study showed an increase of incidence rate for sympathetic nervous system 
tumors from 5.2 per million children per year in 1968-77 to 6.4 in 1978-87 which 
remained fairly constant at 6.3 in 1988-97. The nationwide screening for 
neuroblastomas (NB) by early detection have brought increasing incidence of NBs 
among infants in Osaka, Japan and in Quebec, Canada (Honjo et al., 2003; Woods et 
al., 2002). In contrast to their increasing trends, the slight change in incidence of NBs 
since the 1980s may be explained by either insufficient early detection or the constant 
level suggesting a saturation of incidence in Singapore. The incidence peak of NBs in 
our study is in 1-4 years age group instead of 0-1 year infants which also reveals that 
early detection of such tumors is low locally. The interpretation of increasing trend of 
infant NBs should be careful in that it may not reflect the more NB cancers over time. 
These infant NBs tend to regress spontaneously. The increase in infant NBs may be 
due to earlier diagnosis and reporting of tumors that previously regressed before being 
dectected (Brodeur et al., 1997).  
 
Though hepatic tumors were the rarest type of childhood cancer in Singapore, the 
incidence is seen to increase over the three decades from 1.4 to 2.7 per million 
children per year. The increase is found mainly in boys, whereas the incidence rates 
for girls hardly changed from 1978-87 to 1988-97. In contrast, it was reported in 
Taiwan that vaccination against hepatitis B reduced childhood HCC in both boys and 
girls after the large-scale hepatitis B vaccination in 1984 (Lee et al., 2003). In 
Singapore, the hepatitis B vaccination has been administered to all newborns since 
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1987. Decreases in incidence rates for adult primary liver cancers have been observed 
since then (Goh, 1997). The decreasing trends were not seen in childhood hepatic 
cancers in this study. Since the majority of hepatic tumors in children are 
hepatoblastomas, which are unrelated to HBV infections, Hep B is not likely to be the 
major determinant of incidence rates. On the other hand, the small number of cases in 
each decade may also lead to unstable trends.  
 
The overall incidence of germ cell and gonadal tumors of Singapore increased from 
3.6 per million in 1968-1977, to 4.1 per million in 1978-87, and to 11.0 per million in 
1988-1997. Improved ascertainment may lead to overall increasing rates that we 
observed. The subgroup of intracranial and intraspinal germ cell tumors, which often 
appear in the pineal area, accounted for 15% of the group of germ cell tumors. The 
subgroup of ‘other and unspecified non-gonadal germ cell tumors’, which usually 
diagnosed at mediastinum, retroperitoneum, and sacrococcygeal regions, accounted 
for 14% of the group in our study. To diagnose these two subgroups of tumor (near 
30%), besides the advent of new diagnostic like CT and MRI modalities, surgical 
techniques and methods of pathological diagnosis consequently brought an increase in 
the frequency of diagnosis of such tumors. (Cho et al., 2002). In study by SEER 
(1999), the increase between 1975-79 and 1990-95 for children younger than 15 years 
was mainly resulted from higher rates in intracranial and intraspinal germ cell tumors 
and in non-CNS extragonadal germ cell tumors. The increases were believed to be 
due to increasing recognition by pathologists’ careful scrutiny. 
In this study, there showed two clustering of cases. One clustering is of gonadal germ 
cell tumors and carcinomas in 0-4 years old boys, another clustering is of gonadal 
germ cell tumors in 10-14 years old girls. The increasing cases in these two clustering 
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germ cell tumors most likely caused the sharp increase of incidence rates over time. In 
the study by Muir et al. (1995) based on the West Midlands Regional Children’s 
Tumor Research Group, a special regional registry, the incidences changes described 
for malignant pediatric germ cell tumors in the north-west of England from 1957 to 
1992. They found significant increase in average ASRs from the first half period of 
1957-74 to the second half period of 1975-1994. The significant increase in 0-4 boys 
was thought largely due to the increase in the number of testicular tumors (one type of 
gonadal germ cell tumors, the commonest form of germ cell tumors in this age group 
boys). While the significant increase in the 10-14 age group was largely due to the 
increase in ovarian tumors (one type of gonadal germ cell tumors, the commonest 
form of germ cell tumors in this age group girls). The increasing trend of childhood 
ovarian germ cell tumors may be related to the decreasing age of menarche, which has 
been gradually decreasing worldwide over the century (Wellens et al., 1990; Muir et 
al., 1995). 
 From the results of SEER, there was a slight increase of ASR for germ cell and 
gonadal tumors from 3.7 of 1975-79 to 5.4 of 1990-1995 in USA (SEER, 1999) 
However, the ASR reached to 11.0 during the period of 1988-1997 in Singapore. Are 
Asians more predisposed to the germ cell and gonadal tumors? Thus far there have 
not been much detailed studies to answer this question. It was suggested in study by 
Muir et al. (1995) that the excess incidence of malignant germ cell tumors in Asian 
children could be due to hormonal development or additional ethnic genetic 
influences. In one study evaluating cancer occurrence in Southeast Asian children, 
researchers found that the germ cell tumor rate for 1988 to 1992 was higher in Asians 
(9.9 per million) than that in non-Hispanic whites (4.8 per million) by using the 
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population-based California Cancer Registry (Ducore et al., 2004). The reasons 
behind these findings need to be investigated in future.  
 
Improved diagnostic methods and cancer ascertainment were believed to significantly  
contribute to the increasing trend of incidence for certain types of childhood cancers 
in Singapore. However, there are certain subgroups of childhood cancer consistently 
had lower incidence in Singapore compared to Europe and US. In our study, the 
overall ASR Wilm’s tumor is 3.4 per million over the thirty years, which was lower 
than that for the US black children (8.8 per million), and the US White children (8.1 
per million) by SEER 1974 to 1991(SEER, 2005). It was noted in other studies that 
the incidence of Wilm’s tumors was very much lower in East Asian registries than 
that in White Caucasian populations (Parkin 1988b; Stiller & Parkin 1990, Stiller 
1991). The incidence of childhood cancers in Southeast Asian children were 
compared with non-Hispanic white, black, Hispanic children (1988-92) based on 
California Cancer Registry. The average annual incidence rates of Wilm’s tumor in 
Asians was two-third lower (3.1 vs. 9.2 per million) but significance was not 
presented (Ducore et al., 2004).   
 In this study, the M/F ratio for Wilm’s tumor is 1.5. There showed higher incidence 
of Wilm’s tumor in Asian boys than in Asian girls with sex ratio (M/F) of 1.4 for all 
the cases from 11 series of Asian registries from Japan to Singapore; whereas the 
Wilm’s tumor was equally common to boys and girls in elsewhere children (Stiller & 
Parkin, 1990). The ethnic incidence difference instead of geographical difference in 
Wilm’s tumor suggested that genetic predisposition play an important role in the 
etiology (Stiller & Parkin, 1990; Linet et al. 2003). 
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For of malignant bone tumors, the ASRs were 2.8 per million in osteosarcoma and 0.2 
per million in Ewing’s sarcoma in this study. There were 63 cases of osteosarcoma  
and only 5 cases for Ewing’s sarcoma over the thirty years. The incidence of 
osteosarcoma is much more common than that of Ewing’s sarcoma with the O/E ratio 
of 12.6. It was observed that the O/E ratio was very high in black and East Asian 
population due to the low incidence of Ewing’s sarcoma in these populations (Parkin 
et al., 1993). The incidence rates of osteosarcoma were also found to be lower in 
Asian populations than those in Europe, North America or Australia. Yet no known 
agents were found to explain the geographic variations (Parkin et al., 1993). The ASR 
of Ewing’s sarcoma in Singapore is similar with 0.4 per million for black children in 
the US (SEER, 2005), but lower than 3.2 per million for the White children. Black 
residents of New York State (1975-1980) had significantly lower incidence of 
Ewing’s sarcoma than whites (Polednak, 1985). Incidence rates were found to be low 
the Chinese population (Li et al., 1980) and in Black population (Linet et al., 2003). It 
was also observed in the study to compare the relevant data from registries in China, 
Japan, and the US, the incidence of Ewing sarcoma was lower in Asians than in 
western people (significance not tested) (Guo et al., 1999). A racial predisposition 
was strongly suggested by these findings in the etiology of Ewing’s sarcoma (Parkin 
et al., 1993). 
 
Our study showed that there are significant differences among the incidence rates of 
different ethnic groups of children with all cancers or leukemia (Table 6, Pg 43). Due 
to the low proportion of Malay and Indian children over the total population, and 
limited number of cancers of races other than Chinese in most of the groups of 
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childhood cancers, all data was calculated together for incidence rates and survival 
rates of childhood cancers diagnosed in Singapore from 1968 to 1997.  
The 5-year RSRs are 48.9% (95% CI: 39.9-57.9%) for Chinese children, 50.2% (95% 
CI: 31.6-68.9%) for Malay children and 50.1% (95% CI: 23.7-76.5 %) for Indian 
children. To get a significant difference comparing the RSRs between Chinese and 
Malay children, a sample size of 22810 cases is needed at α=0.05 level with power of 
0.8. So is a sample size of 26717 cases needed to compare the RSRs between Chinese 
and Indian children; 3949516 cases for Malay and Indian children. This study is under 
powered to show statistically significant difference in the ethnic-specific RSRs.  
The information on trends of mortality together with the incidence of childhood 
cancers helps to validate the estimates of survival. This study does not include 
information on mortality rates of childhood cancers. As certain groups had limited 
number of cases showing unstable trends of survival, further studies on mortality of 
childhood cancers are needed to provide useful information and help validate the 
reliability of such trends. 
 
Survival 
To calculate survival, the vital status of registered cases must be followed up to assess 
whether the cases are alive or dead. The vital status of paediatric patients was 
retrieved from Singapore Death Registry. This is the only follow-up information, and 
is called ‘passive follow-up’. This is a limitation of this study, which may lead to 
underestimation of paediatric patients’ deaths, that is, overestimate of the true survival 




This study showed a marked improvement of survival of many groups of childhood 
cancers in Singapore from the seventies to the nineties. In the early stages of 1970s, 
the practice of pediatric medicine in Singapore was just started. The treatment to 
children with cancers was mainly comprising of providing supportive care like blood 
transfusions. In the 1980s, better cure rates were obtained for most childhood cancers 
including leukemia and solid tumors, which was due to the introduction of dedicated 
services to treat children with cancers and specific protocols to diagnose specific 
cancer groups. In the early 1980s the department of Pediatric Surgery was established, 
together with the introduction of safer general anesthesia for children, survival 
improved a lot in childhood solid tumors. Intensive multi-agent chemotherapy 
regimes such as United Kingdom Acute Lymphoblastic Leukemia (UKALL) protocol 
were used for leukemia. Bone marrow transplants (BMT) for children were also been 
carried out in the Hematology Department of Singapore General Hospital (SGH) 
since 1985. Since the opening of the Children’s Hospital in Singapore in 1997, 
tremendous improvements were observed in many childhood cancers like ALL, germ 
cell tumors and Wilm’s tumor with intensive chemotherapy (Tan AM, 2002). While 
this study only includes data till 1997, better survival rates are expected from studies 
on later data. 
 
The 5-year relative survival rates of leukemia also increased in Singapore from 24.8% 
(95%CI: 18.7-32.0%) in 1968-77 to 40.4% (95%CI: 33.2-48.2%) in 1978-87 to 58.2% 
(95%CI: 50.8-65.2%) in 1988-97. Based on local reports, the prognostic of childhood 
ALL prior to 1973 is poor and palliative (Singapore Pediatric Society celebrates its 
Golden Jubilee, 2002). The protocol using multi-agent chemotherapy with cranial 
irradiation and intrathecal methotrexate as CNS directed therapy for childhood ALL 
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was adopted in Dept of Paediatrics, NUS from 1973-1982. Altogether 49 children 
patients from 1973-1981 were included into the cohort study by Department of 
Pediatrics, NUS. A high 5-year survival rate was achieved up to 59% (Quah et 
al.,1983). For higher risk patients, intensified additional therapy with 4-drug induction 
consisting of cyclophosphamide, vincristine, cytarabine and prednisolone (COAP) 
and intensification of maintenance phase with pulsing of vincristine, prednisolone and 
IT chemotherapy. 
In another study by Singapore General Hospital, 25 cases of childhood ALL from 
1976-1981 were included in the study. The median survival figures for childhood 
ALL from 1975-1980 is 43 months in Department of Pediatrics, SGH (Tan, 1982). A 
similar regimen for ALL in SGH from 1975-1980 was a modified Acute Leukemia 
Group B protocol, which consisted of vincristine and prednisolone for induction, 
prophylactic CNS therapy with intrathecal methotrexate, maintenance combination 
chemotherapy with daily 6 mercaptopurine and weekly methorexate, and 
reinforcement doses of vincristine, prednisolone and intrathecal methotrexate during 
maintenance. 
The introduction of chemotherapy undoubtedly improved the survival rates of 
childhood ALL; improved stratification of patients, CNS prophylaxis and intensified 
medical care contributed tremendously to the improved prognosis.  
It is noteworthy that dedicated inpatient facility for children with cancer was 
established in NUH. The 9-bedder unit with 2 isolation rooms in Pediatric Intensive 
Care Unit and 7 beds with isolation facilities together with well-trained dedicated 
nurses in pediatric oncology helped to greatly reduce hospital acquired infections. 
As more children are cured, risk stratification became more important, and further 
researches on improving systematic therapies were carried out in NUH. Cytogenetic 
 62 
analysis became routine to detect the presence of genetic abnormalities. The 
immunophenotyping facility was also set up in 1990 in NUH. Currently, much more 
sensitive markers, detection of minimal residual disease (MRD), were used to detect 
levels of leukemia cells beyond conventional light microscopy of 5% blasts. Patients 
can be accurately stratified into Standard, Intermediate and High risk groups after just 
1 month’s therapy using MRD markers with significantly different prognosis (Yeoh & 
Quah, 2002). This allow for tailored therapy to maximize cure and minimize side 
effects. 
 
Survival for children with ANLL was substantially lower than that for children with 
ALL. The 5-year RSRs for ANLL decreased from 21.9% (95% CI: 13.5-33.5%) in 
1968-77 to 11.9% (95%CI: 5.2-25.0%) in 1978-87, then increased to 31.3% (95%CI: 
19.2-46.8%). The long term Event free survival (EFS) of AML in Singapore was poor 
with chemotherapy alone (Quah et al., 1996). The median survival duration of 5 
ANLL cases was 7 months with a range of 3 months to 22 months from 1975-1980 
(Tan, 1982).  
The realization of the need during induction for virtual marrow aplasia in order to 
obtain a remission, and combination chemotherapy and CNS prophylaxis have been 
achieved to the better prognosis of childhood AML. In this study, the lack of effective 
maintenance therapy was considered the major obstacle for long-term survival in 
AML. The introduction of more intensive MRC AML 10 protocol has improved 
outcome in NUH from 30% to 60% (Tan et al. 2004).  
A later report on one AML case on bone marrow processing for autologous BMT 
suggested a new frontier in management of AML in children by incorporation of early 
 63 
intensive chemotherapy with autologous bone marrow transplantation and high-dose 
melphalan conditioning regimen (Quah et al., 1997). 
 
Improved survival of leukemia have been reported in studies worldwide, the 5-year 
relative survival rates of leukemia increased from 20-30% in 1960s to 60-75% in 
1990s in US and European countries (Gatta et al., 2001; Pastore et al., 2001b; Stiller, 
1994; and Valsecchi et al., 2004).  A number of improvements in treatment such as 
identification of increasingly effective methods of central nervous system prophylaxis 
and identification of the contribution of treatment intensification to improved outcome 
for selected groups of patients were believed to contribute to the improved survival 
rate in SEER (SEER, 1999). The 5-year relative survival rates of leukemia also 
increased in Singapore from 24.8% (95%CI: 18.7-32.0%) in 1968-77 to 40.4% 
(95%CI: 33.2-48.2%) in 1978-87 to 58.2% (95%CI: 50.8-65.2%) in 1988-97. The 
improvement of survival rates for leukemia in Singapore was not as dramatic as that 
in US and Europe. Survival here in the 1970s was similar with those in Japan at 
around 40%, but they were much lower than the 60% in SEER. In the 1990s, though 
the overall 5-year survival rate for leukemia increased nearly 20% in Singapore, the 
changes was about 10% less than those in Japan, and 20% less than those in SEER. 
The survival rate of leukemia in Singapore was still lower compared to these 
countries (Ajiki et al., 2004; SEER, 1999). (Table 11) The survival rates of children 
with ANLL increased 10% over the thirty years from 21.9% in 1968-77 to 31.3% in 





Table 11. 5-year survival in SEER * and Osaka*, Japan in 1975-84 and 1985-94 
 SEER  Osaka, Japan 
 1975-84 1985-94  1975-84 1985-94 
ALL 61 77 39.9 67.6
ANLL 23 41 16.0 42.2
NHL 56 72 43.2 66.0
CNS tumors 60 65 54.6 67.5
Neuroblastoma 54 64 35.7 74.5
Renal tumors 48 83 68.6 75.2
Osteosarcoma 50 63 / /
Soft tissue sarcomas 69 71 61.2 62.9
Germ cell tumors 77 88 44.6 75.3
* SEER, 1999; Ajiki et al., 2004.  
One reason for lower survival may be because of insufficient supportive care for 
children with cancer in Singapore. The expenditure on health here is far below Europe, 
USA and Japan, and unlike these countries where there is socialized medicine and 
high insurance coverage, Singapore patients have to pay a significant portion of the 
medical expenditure. Till late 1990s, children with cancer were not treated in 
dedicated facilities, and these immunocompromised patients were nursed in the same 
exposed environment with patients with pneumonia and diarrhea. It was not surprising 
that deaths due to infection caused high mortality (Lou et al., 1994).  
Another reason may be the adoption of inferior treatment protocol like UKALL X (4 
weekly doses of Vincristine, 2 consecutive doses of Daunorubicin, 9 doses of 1-
asparaginase and four weeks of Prednisolone for induction therapy). There was a 
tremendous change in treatment of childhood ALL in the 1980s and 1990s. The 
UKALL X system of intensive therapy adopted by 3 centres in Singapore (Lou et al., 
1994) had relatively poorer outcome compared to the BFM-ALL therapy system. A 
clinical trial study was conducted on 87 patients of childhood ALL collected from 
three main hospitals in Singapore from 1986 to 1992. The overall 5-year cumulative 
survival rate was 58%, which was 7% lower than the estimate from UKALL trials. 
The lower survival rate was due to high mortality from infection and a high relapse 
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rate in the low risk group patients (Lou et al., 1994). Using the same treatment 
protocol of UKALL X, the event-free and overall survival rates of all patients 
diagnosed between 1985 and 1992 at 7 years were 66% (95%CI 53–76) and 75% 
(95%CI 63–84), respectively in the hospital-based study in Hong Kong (Shing et al., 
1999).  
The relative lower survival is because the UKALL X therapy invokes highly intensive 
intensification blocks which caused increased infective morbidity and mortality 
especially in poorer supportive care environment. The NUH ALL treatment regimens 
on the other hand are much less intensive with mild intensification blocks compared 
to UKALL. The treatment outcome of 66 children with acute leukemia in 1988-93 
was evaluated. The 2-year disease-free survival (DFS) was high at 62% for ALL. The 
major cause of treatment failure was relapse of leukemia (Quah et al., 1996). This 
regimen with less toxic deaths but similar relapse rates resulted in better overall EFS 
than UKALL X in Singapore (Lou et al., 1994). 
 According to the result of our study, it was suggested that more attention was to be 
paid to administration of intensive supportive care for the delivery of intensive 
chemotherapy regimens, reduction of therapy-related toxicity, and prevention of 
nosocomial infections. The situation of children cancer patients’ attendance has been 
much improved since 2000. With limited health care budgets, working with careful 
organizations to improve supportive care and social support is instrumental. The 
Children’s Cancer Foundation together with NUH set up a dedicated treatment facility 
for children with cancer. The KK Women’s and Children’s Hospital also have 
specialized wards to patients with cancer. These specialized and dedicated areas 
allows delivery of complex therapy and improve compliance to therapy. Infective 
complications and deaths have been reduced significantly due to systematic early 
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treatment of neutropenic fever with broad spectrum antibiotics. Improved care for 
central lines and nursing care has resulted in reduced line infections and blood culture 
positive results, which brought lower infective deaths (Tan et al., 2003). The girls had 
better survival than boys with leukemia, this was believed to be attributed to 
biological features with reasons still unclear (Pui et al., 1999). 
The survival for NHL showed marked improvement from 21.7% in 1968-77 to 40.7% 
in 1978-87 to 76% in 1988-97. This result is comparable with those in US and Europe. 
The increasing trends were also seen in studies in Europe. (Pastore et al., 2001a, b; 
Stiller & Bunch, 1990) The introduction of LMB protocol by the French group (Patte, 
1998) has resulted in marked improvement in treatment of childhood NHL. This 
protocol has been uniformly adopted by most countries in the world, which made the 
survival of NHL comparable world wide. The introduction of aggressive combination 
chemotherapy has changed the prognosis of NHL (Samuelsson et al., 1999). Recent 
efforts have concentrated on determining which groups of patients would be cured by 
less intensive treatment (Lilleyman & Pinkerton, 1996). The 5-year survival in 
Singapore in the 1970s was similar to that in Osaka, but it was 8% higher in the 1980s. 
It is believed that the treatment locally is comparable with Europe and US. The 
histologically accurate diagnosis and classification of NHL together with the 
advanced chemotherapy protocols are believed to have improved the prognosis of 
NHL greatly. 
The CNS tumor survival, as a whole, showed gradual improvement during the last 30 
years, although this trend was not as obvious as those in U.S.A. and Nordic European 
countries (Ries et al., 1999).  The 5-year survival rates CNS tumors increased over the 
thirty years in Singapore from 38.4% (95% CI: 27.7-50.3%) in 1968-77, to 40.1% 
(95% CI: 30.6-50.4%) in 1978-87, to 49.9% (95%CI: 40.2-59.7%) in 1988-97. A 
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better combination and administration of each therapeutic approach, such as the 
excision of the tumor, radiotherapy, and chemotherapy, are the primary reasons of the 
improvement (Pastore et al., 2001b; Parker, 1997). Improved neurosurgical 
microsurgical techniques and neuroanaesthesia and improved diagnostic imaging 
tools like CT and MRI scan all contribute to the improvement of survival of CNS 
tumors locally. The boys and girls had similar survival rates of 43.7% and 43.9% in 
our study. While there is minimal difference in survival of CNS cancers by sex in 
SEER study (SEER, 1999), age is an important prognostic factor. Very young age 
exhibited the poorest prognosis in studies of developed countries (SEER, 1999; 
Magnani et al., 2001b). The poorest outcome is 30.5% for infants. Infants and young 
children do poorer because they are not given radiotherapy as radiotherapy delivered 
to a developing brain less than 3 years old is associated with severe long-term 
complications and brain damage. Infant brain tumors are highly malignant and 
infiltrative. It is difficult to get a good clear margin. Infant brain tumors are very 
vascular while the baby’s blood volume is very small. Aggressive surgery is 
associated with excessive blood loss relative to the baby’s blood volume and is poorly 
tolerated. Infant brain is still developing and cannot tolerate radiotherapy which is the 
second most important modality of therapy after surgery. The avoidance of 
radiotherapy makes it difficult to destroy residual disease (Strother et al. 2002). 
Chemotherapy is usually not very effective in brain tumors though certain baby brain 
protocols have been developed. (Rutkowski et al., 2005) 
According to the data from different countries, including Singapore, the 
improvements in survival of CNS tumors were still modest compared with those of 
ALL. Doctors have to improve the rate of early diagnosis of CNS tumors especially in 
small children. There is an inherent difficulty in diagnosing the disease in patients 
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without neurological representations; therefore later detection may eventually result in 
a higher mortality (Tan et al., 1991). The dense neurological network also makes it 
highly susceptible to damage by tumor and surgery, which brings the difficulty of 
managing the CNS tumor. Also the blood brain barrier prevents penetration of high 
levels of chemotherapy drugs into the brain; the child’s brain which is still growing 
and maturing and is severely damaged by side-effects of radiation therapy. From the 
viewpoint of treatment, treatment strategies for CNS tumors lagged behind childhood 
ALL in the last two to three decades. Furthermore, many kinds of CNS tumors 
localize to dangerous sites, such as the hypothalamic region and the brain stem region, 
and are inaccessible to operative excision which is the requisite for cure. These 
considerations could explain the relatively unsatisfactory improvement of CNS 
tumors compared to ALL.  
So far, there is still a gap between Singapore and the advanced countries in terms of 
survival for CNS tumors. The Singaporean lag could reflect the imperfect 
organization of medical care for CNS tumors and the reluctance of some pediatric 
oncologists to utilize aggressive and toxic treatments for their patients (Terracini et al., 
2001).  Other clinical studies have indicated that either combining various specialists 
for treating childhood cancers or the training of a neurosurgeon in pediatric versus 
adult neurosurgery can improve the patients’ survival (Magnani et al., 2001b). 
Unfortunately in Singapore, there is not a dedicated pediatric neuro-oncology surgeon. 
The lack of a dedicated team of doctors managing brain tumors in children is probably 
the main reason for the lag of survival of CNS tumors. However, to our knowledge, 
there are no papers summarizing the current diagnosis and treatment of childhood 
CNS tumors in Singapore. In future, standard protocols about dealing with this group 
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of cancers should be established so that comparison with the situation in other 
countries may be easily carried out.  
In our study, infants with neuroblastoma had highest survival rate of 76.8% (95% CI: 
57.1-89.5), which was also observed in other studies (SEER, 1999). The favorable 
outcome for infants with neuroblastoma reflects the favorable biological 
characteristics of neuroblastomas in this age group (Brodeur & Castleberry, 1997). In 
Japan, the nationwide screening of infants for neuroblastoma started from 1984. This 
over-diagnosed patients with neuroblastoma who have excellent outcome which 
affected an apparent increase in its incidence and survival (Ajiki et al., 2004). 
Comparison of survival of neuroblastoma in Japan should be evaluated carefully, and 
taking the over-diagnoses into consideration. Unfortunately infant neuroblastoma 
screening picked up the good prognosis spontaneously regressing tumors without 
decreasing the incidence of late onset, poorer prognosis ones. 
The 5-year survival rates of renal tumors increased from 54.6% (95% CI: 35.3-72.6) 
in 1968-77, to 74.0% (95% CI: 51.4-88.6) in 1978-87, to 76.5% (95% CI: 55.2-89.7) 
in 1988-97. The survival rate had reached a high level in the last twenty years, which 
is also comparable with 75.2% in Osaka and 83% in SEER for 1984-94. Although 
Wilm’s tumor is rare, the intergroup combined studies (the National Wilm’s Tumor 
Studies and SIOP studies) have made great headways in therapy of this childhood 
cancer. In future, more study can be done on exploration of less toxic and more 
affordable therapies for good risk cases.  
The overall 5-year survival rate (88.5% 95%CI: 77.9-94.5%) for children with germ 
cell and gonadal tumors during 1988-1997 is comparable to the result of SEER from 
USA (84%).  Increasing survival rates were observed in the world in the past several 
decades. In USA the total survival rate increased from 77% in the period of 1975-84 
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to 88% in 1985-94 for the patients younger than 20 years of age. Most researchers 
believe that this improvement is due to the widespread use of platinum-based 
chemotherapy, which is particularly effective against germ cell tumors (Mann et al., 
1998; Schmoll et al., 2004; Suita et al., 2002) In addition, surgical measures together 
with chemotherapy and/ or radiotherapy could achieve the best results for the 
advanced tumors. From another perspective, Lim et al (2002) believe high survival 
rates may be contributed by the majority patients with early stage I tumors which 
were able to be completely resected. The overall survival rates of infants are higher 
those of other age groups in Singapore. One Japanese study also pointed out that 
diagnosis under 1 year of age was one of the favorable prognosis factors for malignant 
germ cell tumors (MGCT) in childhood from 1975 to 2000 (Suita et al., 2002). Since 
the mid-1980s MRI has become the diagnostic imaging modality of choice, 
microsurgical techniques have ben developed, and hemostatic agents that can control 
intracranial pressure and intraoperative monitoring devices have been improved. 
 
The survival of children with osteosarcoma remains dismal in our study. The use of 
amputation instead of limb salvage surgery may result in poor acceptance of therapy 
and high abscondence. The trial of the NUH/NUS team using reconstructive or limb 
salvage surgery recently will probably improve the outcome (Chang et al., 2002). It 
has been confirmed by EUROCARE studies that there have been little further 
improvement of survival of osteosarcomas in recent years after substantial increase 
till early 1980s (Stiller et al., 2001a). Improvement was also observed in survival rates 
for bone cancers in children by SEER (1999). While improvement was expected 
locally, yet decreased survival was observed in the third decade of this study which 
may be due to random variation by a small number of cases in that period of time. 
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Improvement of survival rates for soft tissue sarcomas was observed in studies by 
EUROCARE though inter-countries differences presented among European countries 
(Stiller et al., 2001b). While there was little improvement (non-significant) of survival 
rates of soft tissue sarcomas in studies by SEER and Osaka, Japan over time (SEER, 
1999; Ajiki et al., 2004). In study by SEER (1999), no difference was observed for 
either the fibrosarcoma subcategory or for the “other specified” soft tissue sarcoma 
subcategory from 1975-84 to 1985-94, except for a small survival improvement in 
rhabdomyosarcoma occurred from the earlier to the later period. In this study, slight 
decrease of survival rates for all soft tissue sarcomas combined was observed in the 
third decade following the marked increase from the first decade to the second. The 
slight decease is difficult to explain as it may be due to changes of relatively large 












Chapter 6   Conclusion 
Our study showed an increasing trend for most childhood cancers over thirty years, 
such as leukemia, CNS tumors, sympathetic nervous system tumors, retinoblastoma, 
hepatic tumors, and ‘germ cell and gonadal neoplasms’. The improvements of 
diagnostics like trained personnel for full blood counts and bone marrow morphology 
and imaging like CT scan and MRI will undoubtedly improve the diagnosis of 
childhood cancers. CNS tumors, followed by germ cell and gonadal neoplasms and 
leukemia which require much more intensive diagnostic techniques than other tumors 
as the incidence rates increased greatly over the three decades. Improved cancer 
ascertainment by cancer registry was also believed to contribute to the increase of 
incidence for childhood cancers. The overall incidence of childhood cancers in 
Singapore had increased markedly over the 30-year period. This result was 
comparable with those of other western and Asian countries.  
This study showed a marked improvement of survival of many groups of childhood 
cancers (ALL, ANLL, NHL, CNS tumors, NB, renal tumors and germ cell tumors) 
from 1968 to 1997. The survival rates for leukemia in Singapore were still lower than 
that in the US and European countries. The reason may be because of insufficient 
supportive care for children with cancer in Singapore and the adoption of inferior 
treatment protocol like UKALL X. Due to the lack of publications related to the 
treatment of other childhood cancers, it is difficulty to analyzing the reason or making 
comparison with other countries. The population-based cancer registry is an important 
tool to monitor incidence and survival of cancers in the population. It is hoped that 
this thesis will provide the impetus of the local pediatric oncologists to do more future 
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Appendix 1. No. of cases, Relative frequencies, Rate per million and MV% of childhood cancers (1968-1997)                                          
 No.  of  cases Rel. freq. (%) Rate  Per  million MV% 
 0 1-4 5-9 10-14 All M/F Overall Group 0-4 5-9 10-14 crude ASR Cum  
I. Leukemia 47 342 252 172 813 1.4 38.2 100 61.3 36.4 25.0 40.1 42.7 614 88.6
Lymphoid 26 247 176 108 557 1.4 26.2 68.5 43.0 25.4 15.0 27.5 29.2 417 91.6
Acute non-lymphocytic 12 64 53 44 173 1.4 8.1 21.3 12.0 7.7 6.3 8.5 9.0 130 81.5
Chronic myeloid 2 12 10 16 40 1.7 1.9 4.9 2.2 1.5 2.3 2.0 2 30 95.0
Other  specified 0 2 1 0 3 0.5 0.1 0.4 0.3 0.1 0 0.2 0.2 2 66.7
Unspecified 7 17 12 4 40 1.1 1.9 4.9 3.8 1.7 0.6 2.0 2.2 31 72.5
   
II. Lymphomas 11 51 69 77 208 2 9.8 100 9.8 10.0 11.0 10.3 10.2 154 89.9
Hodgkin’s disease 0 5 14 18 37 2.7 1.7 17.8 0.8 2.0 2.6 1.8 1.7 27 94.9
Non-Hodgkin lymphoma 7 28 37 42 114 1.7 5.4 54.8 5.5 5.4 6.0 5.6 5.6 85 95.6




0 0 0 1 1 0 0.1 0.5 0 0 0.1 0.1 0 1 100.0
Unspecified lymphoma 4 12 15 14 45 2 2.1 21.6 2.5 2.2 2.0 2.2 2.3 34 68.9
   
III. Brain and spinal 
neoplasms 23 63 129 88 303 1.1 14.2 100 13.5 18.7 13.0 15.0 15 226 78.2
Ependymoma 4 8 10 6 28 0.9 1.3 9.2 1.9 1.5 0.9 1.4 1.5 22 96.4
Astrocytoma 7 21 41 35 104 1 4.9 34.3 4.4 5.9 5.0 5.1 5.1 77 97.1
Primitive 
neuroectodermal tumors 8 17 38 17 80 1.2 3.8 26.4 3.9 5.5 2.4 4.0 4.0 59 92.5
Other glioma 0 4 13 9 26 1 1.2 8.6 0.6 1.9 1.3 1.3 1.2 19 88.5
Other specified 0 1 5 3 9 2 0.4 3.0 0.2 0.7 0.4 0.4 0.4 7 100.0
Unspecified 4 12 22 18 56 1.4 2.6 18.5 2.5 3.2 2.6 2.8 2.8 42 5.36
   
IV. Sympathetic nervous 
system tumors 29 50 17 8 104 1.1 4.9 100 12.4 2.5 1.1 5.1 5.9 80 90.4
Neuroblastoma 29 48 15 3 95 1.3 4.5 91.3 12.1 2.3 0.4 4.7 5.5 74 93.7
Other 0 2 2 5 9 0.3 0.4 8.7 0.3 0.3 0.7 0.4 0.4 7 55.6
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 No.  of  cases Rel. freq. (%) Rate  Per  million MV% 
 0 1-4 5-9 10-14 All M/F Overall Group 0-4 5-9 10-14 crude ASR Cum  
V. Retinoblastoma 9 59 3 0 71 1 3.3 100 10.7 0.4 0 3.5 4.3 56 98.6
   
VI. Renal tumors 16 38 8 3 65 1.4 3.1 100 8.5 1.2 0.4 3.2 3.8 51 90.8
Wilms’ tumors 15 35 5 2 57 1.5 2.7 87.7 7.9 0.7 0.3 2.8 3.4 45 100.0
Renal carcinoma 0 1 0 1 2 0 0.1 3.1 0.2 0 0.1 0.1 0.1 2 100.0
Unspecified 1 2 3 0 6 0.5 0.3 9.2 0.5 0.4 0 0.3 0.3 5 0
   
VII. Hepatic tumors 13 8 9 5 35 1.9 1.6 100 3.3 1.3 0.7 1.7 1.9 27 91.4
hepatoblastoma 12 8 4 0 24 1.4 1.1 68.6 3.2 0.6 0 1.2 1.4 19 87.5
Hepatic carcinoma 1 0 5 5 11 4.5 0.5 31.4 0.2 0.7 0.7 0.5 0.5 8 100.0
Unspecified 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
   
VIII. Malignant bone 
tumors 1 7 16 62 86 0.8 4.0 100 1.3 2.3 8.9 4.3 3.8 63 100.0
Osteosarcoma 0 3 13 47 63 0.8 3.0 73.3 0.5 1.9 6.7 3.1 2.8 46 100.0
Chondrosarcoma 0 0 1 2 3 0.5 0.1 3.5 0 0.1 0.3 0.2 0.1 2 100.0
Ewing’s sarcoma 0 2 0 3 5 4 0.2 5.8 0.3 0 0.4 0.3 0.2 4 100.0
Other specified 0 1 0 10 11 1.2 0.5 12.8 0.2 0 1.4 0.5 0.5 8 100.0
Unspecified 1 1 2 0 4 0.3 0.2 4.7 0.3 0.3 0 0.2 0.2 3 100.0
   
IX. Soft tissue sarcomas 9 28 31 44 112 0.8 5.3 100 5.8 4.5 6.3 5.5 5.5 83 98.2
Rhabdomyosarcoma 5 21 16 12 54 1.2 2.5 48.2 4.1 2.3 1.7 2.7 2.8 41 98.2
Fibrosarcoma 1 3 8 15 27 0.6 1.3 24.1 0.6 1.2 2.1 1.3 1.2 20 100.0
Kaposi’s sarcoma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other specified 3 3 6 14 26 0.6 1.2 23.2 0.9 0.9 2 1.3 1.2 19 96.2









 No.  of  cases Rel. freq. (%) Rate  Per  million MV% 
 0 1-4 5-9 10-14 All M/F Overall Group 0-4 5-9 10-14 crude ASR Cum  
X. Germ cell and 
gonadal neoplasms 18 38 22 42 120 0.9 5.6 100 8.8 3.2 6.0 5.9 6.2 90 99.2
Intracranial and intrspinal 
germ cell 1 0 7 10 18 1.6 0.9 15.0 0.2 1.0 1.4 0.9 0.8 13 100.0
Other and unspecified 
non-gonadal germ cell 3 11 1 2 17 0.5 0.8 14.2 2.2 0.1 0.3 0.8 1.0 13 94.1
Gonadal germ cell 5 13 10 18 46 0.6 2.2 38.3 2.8 1.5 2.6 2.3 2.3 35 100.0
Gonadal carcinoma 9 13 2 8 32 2.2 1.5 26.7 3.5 0.3 1.1 1.6 1.8 25 100.0
Other and unspecified 0 1 2 4 7 0 0.3 5.8 0.2 0.3 0.6 0.4 0.4 6 100.0
   
XI. Carcinomas and 
epithelial neoplasms 0 8 17 96 121 0.8 5.7 100 1.3 2.5 14.0 6.0 5.4 89 96.7
Adrenocortical  0 1 1 4 6 0 0.3 5.0 0.2 0.1 0.6 0.3 0.3 5 83.3
Thyroid 0 0 6 32 38 0.3 1.8 31.4 0 0.9 4.6 1.9 1.6 28 100.0
Nasopharyngeal  0 1 2 20 23 4.8 1.1 19 0.2 0.3 2.9 1.1 1.0 17 100.0
Melanoma 0 0 0 3 3 2 0.1 2.5 0 0 0.4 0.2 0.1 2 66.7
Skin 0 0 2 1 3 0 0.1 2.5 0 0.3 0.1 0.2 0.1 2 100.0
Other and unspecified 0 6 6 36 48 0.8 2.3 39.7 0.9 0.9 5.2 2.4 2.2 35 95.8
   
XII. Other and 
unspecified neoplasms 16 23 23 29 91 1.2 4.3 100 6.1 3.3 4.2 4.5 4.7 68 22.0
Other specified  2 1 6 8 17 0.7 0.8 18.7 0.5 0.9 1.1 0.8 0.8 13 100.0
Other unspecified 14 22 17 21 74 1.4 3.5 81.3 5.7 2.5 3.0 3.7 3.9 56 4.1
   








Appendix 2. Sex-specific number of cases, Rate per million and MV% of childhood cancers (1968-1997)                    
 Male female 
 No.   of    cases Rate per  million No.  of  cases Rate per million 
 0 1-4 5-9 10-14 all crude ASR cum 0 1-4 5-9 10-14 all crude ASR cum 
I. Leukemia 20 199 150 101 470 45.0 48.0 684 27 143 102 71 343 35.0 37.4 535
Lymphoid 11 147 102 63 323 30.9 33.0 471 15 100 74 45 234 23.9 25.5 365
Acute non-lymphocytic 7 34 37 22 100 9.6 9.9 145 5 30 16 22 73 7.5 7.9 113
Chronic myeloid 1 9 3 12 25 2.4 2.4 36 1 3 7 4 15 1.5 1.5 23
Other  specified 0 0 1 0 1 0.1 0.1 1.4 0 2 0 0 2 0.2 0.3 3
Unspecified 1 9 7 4 21 2.0 2.1 31 6 8 5 0 19 1.9 2.3 30
   
II. Lymphomas 7 29 50 53 139 13.3 13.0 198 4 22 19 24 69 7.0 7.2 106
Hodgkin’s disease 0 4 11 12 27 2.6 2.4 38 0 1 3 6 10 1.0 0.9 15
Non-Hodgkin lymphoma 5 11 28 28 72 6.9 6.7 102 2 17 9 14 42 4.3 4.5 65
Burkett’s lymphoma 0 5 3 1 9 0.9 0.9 13 0 1 0 1 2 0.2 0.2 3
Miscellaneous 
lymphoreticular neoplasms 0 0 0 1 1 0.1 0.1 1.4 0 0 0 0 0 0 0 0
Unspecified lymphoma 2 9 8 11 30 2.9 2.9 43 2 3 7 3 15 1.5 1.6 23
   
III. Brain and spinal 
neoplasms 11 29 73 47 160 15.3 15.0 228 12 34 56 41 143 14.6 14.7 219
Ependymoma 1 4 5 3 13 1.2 1.3 19 3 4 5 3 15 1.5 1.6 23
Astrocytoma 1 11 23 17 52 5.0 4.9 74 6 10 18 18 52 5.3 5.3 80
Primitive neuroectodermal  
tumors 5 7 25 6 43 4.1 4.2 62 3 10 13 11 37 3.8 3.8 57
Other glioma 0 2 7 4 13 1.2 1.2 18 0 2 6 5 13 1.3 1.3 20
Other specified 0 0 4 2 6 0.6 0.5 8.4 0 1 1 1 3 0.3 0.3 5
Unspecified 4 5 9 15 33 3.2 3.1 47 0 7 13 3 23 2.4 2.4 35
   
IV. Sympathetic nervous 
system tumors 17 29 9 0 55 5.3 6.2 83 12 21 8 8 49 5.0 5.6 78
Neuroblastoma 17 28 8 0 53 5.1 6 80 12 20 7 3 42 4.3 5.0 67
Other 0 1 1 0 2 0.2 0.2 3 0 1 1 5 7 0.7 0.7 10
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 Male female 
 No.   of    cases Rate per  million No.  of  cases Rate per million 
 0 1-4 5-9 10-14 all crude ASR cum 0 1-4 5-9 
10-
14 all crude ASR cum 
V. Retinoblastoma 6 28 2 0 36 3.4 4.2 55 3 31 1 0 35 3.6 4.4 57
   
VI. Renal tumors 6 24 5 3 38 3.6 4.2 57 10 14 3 0 27 2.8 3.3 44
Wilms’ tumors 6 22 4 2 34 3.3 3.8 51 9 13 1 0 23 2.4 2.9 37
Renal carcinoma 0 1 0 1 2 0.2 0.2 3 0 0 0 0 0 0 0 0
Unspecified 0 1 1 0 2 0.2 0.2 3 1 1 2 0 4 0.4 0.5 6
   
VII. Hepatic tumors 7 5 7 4 23 2.2 2.4 34 6 3 2 1 12 1.2 1.4 19
hepatoblastoma 7 5 2 0 14 1.3 1.6 21 5 3 2 0 10 1.0 1.2 16
Hepatic carcinoma 0 0 5 4 9 0.9 0.8 13 1 0 0 1 2 0.2 0.2 3
Unspecified 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
   
VIII. Malignant bone 
tumors 0 1 5 33 39 3.7 3.2 54 1 6 11 29 47 4.8 4.4 71
Osteosarcoma 0 0 4 23 27 2.6 2.2 38 0 3 9 24 36 3.8 3.3 54
Chondrosarcoma 0 0 0 1 1 0.1 0.1 2 0 0 1 1 2 0.2 0.2 3
Ewing’s sarcoma 0 1 0 3 4 0.4 0.4 6 0 1 0 0 1 0.1 0.1 2
Other specified 0 0 0 6 6 0.6 0.5 8 0 1 0 4 5 0.5 0.5 8
Unspecified 0 0 1 0 1 0.1 0.1 1 1 1 1 0 3 0.3 0.4 5
   
IX. Soft tissue sarcomas 2 16 12 20 50 4.8 4.8 72 7 12 19 24 62 6.3 6.3 95
Rhabdomyosarcoma 1 13 7 8 29 2.8 2.9 42 4 8 9 4 25 2.6 2.7 39
Fibrosarcoma 0 1 3 6 10 1.0 0.9 14 1 2 5 9 17 1.7 1.6 26
Kaposi’s sarcoma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other specified 1 1 2 6 10 1.0 0.9 14 2 2 4 8 16 1.6 1.6 24







 Male female 
 No.   of    cases Rate per  million No.  of  cases Rate per million 
 0 1-4 5-9 10-14 all crude ASR cum 0 1-4 5-9 
10-
14 all crude ASR cum 
X. Germ cell and gonadal 
neoplasms 15 25 5 11 56 5.4 6.1 83 3 13 17 31 64 6.5 6.3 97
Intracranial and intrspinal 
germ cell 1 0 4 6 11 1.1 1 15 0 0 3 4 7 0.7 0.6 10
Other and unspecified non-
gonadal germ cell 1 2 1 2 6 0.6 0.6 9 2 9 0 0 11 1.1 1.4 18
Gonadal germ cell 5 10 0 2 17 1.6 1.9 26 0 3 10 16 29 3.0 2.7 43
Gonadal carcinoma 8 13 0 1 22 2.1 2.6 33 1 0 2 7 10 1.0 0.9 15
Other and unspecified 0 0 0 0 0 0 0 0 0 1 2 4 7 0.7 0.7 11
   
XI. Carcinomas and 
epithelial neoplasms 0 6 9 37 52 5.0 4.5 73 0 2 8 59 69 7.0 6.1 102
Adrenocortical  0 0 0 0 0 0 0 0 0 1 1 4 6 0.6 0.6 9
Thyroid 0 0 3 6 9 0.9 0.8 13 0 0 3 26 29 3.0 2.5 43
Nasopharyngeal  0 1 2 16 19 1.8 1.6 27 0 0 0 4 4 0.4 0.3 6
Melanoma 0 0 0 2 2 0.2 0.2 3 0 0 0 1 1 0.1 0.1 2
Skin 0 0 0 0 0 0 0 0 0 0 2 1 3 0.3 0.3 5
Other and unspecified 0 5 4 13 22 2.1 2 31 0 1 2 23 26 2.7 2.3 39
   
XII. Other and 
unspecified neoplasms 10 11 14 15 50 4.8 4.9 72 6 12 9 14 41 4.2 4.3 64
Other specified  1 1 2 3 7 0.7 0.7 10 1 0 4 5 10 1.0 0.9 15
Other unspecified 9 10 12 12 43 4.1 4.3 62 5 12 5 9 31 3.2 3.4 49
   
Total 101 402 341 324 1168 111.7 116.2 1693 91 313 255 302 961 98.1 101.5 1486 
 
 
